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The Research work incorporated in the thesis with the title 
“SYNTHESIS AND CHARACTERISATION OF THERAPEUTI- 
CALLY INTERESTED COMPOUNDS” has been described as under. 
[A]   STUDIES ON CHALCONE DERIVATIVES 
[B]   STUDIES ON SCHIFF’S BASE DERIVATIVES 
 
[A]  STUDIES  ON  CHALCONE  DERIVATIVES 
        The chemistry of chalcones containing an active keto-ethylenic linkage 
has been assumed important because of their versatility in the synthesis of 
many heterocyclic compounds. Furthermore, they are also associated with 
wide spectrum of pharmacological activities and industrial applications. The 
chalcones are reported to possess antibacterial, antiviral, agrochemical and 
diuretic activities. They have been found to be applicable for photosensitive 
materials, polymerization catalysts, fluorescent brightening agents, pigments, 
etc. With a view to supplement these valid observations, it was contemplated 
to synthesize some novel chalcone derivatives using 4-(p-Chlorobenzyloxy)-
3-methoxybenzaldehyde with better biological activities which have been 
described as under. 
PART - I : STUDIES  ON  PYRAZOLINES 
      Pyrazoline derivatives are endowed with different therapeutic activities 
such as antibacterial, analgesic, anthelmintic, antiinflammatory, 
antitubercular, etc. These valid observations led us to synthesize some novel  
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pyrazoline derivatives bearing chlorobenzyl derivative, which have been 
described as under. 
SECTION-I : Synthesis and biological evaluation of 1-Aryl-3-[4’-(p-                         
chlorobenzyloxy)-3’-methoxyphenyl]-propenones 
                     
O
O
CH3
Cl
O
R
Type(I) R=Aryl
 
      The chalcone derivatives of type (I) have been synthesized by the reaction 
of 4-(p-Chlorobenzyloxy)-3-methoxybenzaldehyde with different 
acetophenones  in  presence of  40%  NaOH. 
 
SECTION-II : Synthesis and biological evaluation of 1-Acetyl-3-
aryl-5-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-4,- 
5-dihydro-1H-pyrazoles 
                      
N N
O
CH3
O
Cl
R
OCH3
Type(II) R=Aryl
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      The pyrazoline derivatives of type(II) have been synthesized by the 
condensation of the chalcones of type(I) with hydrazine hydrate in glacial 
acetic acid. 
 
SECTION-III : Synthesis and biological evaluation  of  3-Aryl-5-[4’-
(p-chlorobenzyloxy)-3’-methoxyphenyl]-1-(p-fluoro- 
phenyl)-4,-5-dihydro-1H-pyrazoles 
                    
N
N
O
Cl
F
R
OCH3
Type (III) R=Aryl
 
      The synthesis of pyrazoline derivatives of type(III) have been undertaken 
by the cyclocondensation of the chalcones of type (I) with 4-
Fluorophenylhydrazine.        
 
PART - II : STUDIES  ON  CYANOPYRIDINES 
      Cyanopyridine derivatives have attracted considerable attention in view of 
their great therapeutic importance as anticonvulsant, antifungal, antibacterial, 
antidiabetic and hypertensive agents. In order to developing therapeutically  
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important compounds, it was considered of interest to synthesize some new 
cyanopyridine derivatives shown as under. 
 
SECTION-I : Synthesis and biological evaluation of 2-Amino-6-
aryl-4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-3-
cyanopyridines 
                  
N
O
Cl
NH2
N
R
O
CH3
Type (IV)      R=Aryl
 
      Cyanopyridine derivatives of type(IV) have been prepared by the reaction 
of chalcones of type(I) with malononitrile in presence of ammonium acetate. 
 
SECTION-II : Synthesis    and    biological     evaluation   of 6-Aryl- 
              4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2-meth-
oxy-3-cyanopyridines 
 
 
 
 
  
 
5
 
                   
N
O
Cl
O
N
R
O
CH3
CH3
Type (V)      R=Aryl
 
      Cyanopyridine derivatives of type(V) have been prepared by the reaction 
of chalcones of type(I) with malononitrile and sodium methoxide. 
 
SECTION-III : Synthesis and biological evaluation of 6-Aryl-4-[4’- 
                       (p-chlorobenzyloxy)-3’-methoxyphenyl]-2-ethoxy-3-          
cyanopyridines 
                 
N
O
Cl
O
N
R
O
CH3
CH3
Type (VI)      R=Aryl
 
      Cyanopyridine derivatives of type(VI) have been prepared by the reaction 
of chalcones of type(I) with malononitrile and sodium ethoxide. 
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PART - III : STUDIES  ON  PYRIMIDINES : 
      Pyrimidine nucleus possess remarkable pharmaceutical importance and 
biological activities, some of their derivatives occur as natural product, like 
nucleic acids and vitamin B. Pyrimidine derivatives are used for the treatment 
of AIDS and as antitumor agents. These valid observations led us to 
synthesize some novel pyrimidine in search of agents having more biological 
activities which have been described as under. 
 
SECTION–I: Synthesis and biological evaluation of 4-Aryl-6-[4’-(p-             
chlorobenzyloxy)-3’-methoxyphenyl]-1H-pyrimidine-
2-ones 
                   
O
Cl
N
N
H
O
R
OCH3
Type(VII) R=Aryl
 
      Pyrimidinone derivatives of type(VII) have been prepared by the reaction 
of chalcones of type (I) with urea in presence of basic catalyst like NaOH. 
 
SECTION-II : Synthesis and biological evaluation of 4-Aryl-6-[4’-
(p-chlorobenzyloxy)-3’-methoxyphenyl]-1H-pyrimid- 
in-2-thiones 
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O
Cl
N
N
H
S
R
OCH3
Type(VIII) R=Aryl
 
      Pyrimidinone derivatives of type(VIII) have been prepared by the reaction 
of chalcones of type (I) with thiourea in presence of basic catalyst like NaOH. 
 
PART - IV : STUDIES  ON  INDAZOLES 
      Biological importance of indazole derivatives is well known. They have 
been reported to be active as cardiovascular, sedative, antifungal and 
antibecterial. In order to develop medicinally important compounds, it was 
considered of interest to synthesize some new indazoles which have been 
described as under. 
 
SECTION-I : Synthesis and biological evaluation of Ethyl-4-aryl-6-
[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2-oxo-cy- 
clohex-3-ene- carboxylates 
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O
Cl
OO
O
RO
CH3
CH3
Type(IX) R=Aryl
 
      Cyclohexenones of type (IX) have been prepared by cyclocondensation of 
chalcones of type (I) with ethylacetoacetate in the presence of basic catalyst 
K2CO3. 
 
SECTION-II :  Synthesis and biological evaluation of Methyl-4-aryl-
6-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2-oxo-
cyclohex-3-ene-carboxylates 
                
O
Cl
OO
O
CH3
ROCH3
Type(X) R=Aryl
 
      Cyclohexenones of type (X) have been prepared by the cyclocondensation 
of chalcones of type (I) with methylacetoacetate in the presence of basic 
catalyst  K2CO3. 
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SECTION-III :  Synthesis  and  biological  evaluation  of 6-Aryl-4-    
[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2,3,3a- 
,4,5-pentahydroindazole-3-ones 
               
O
Cl
NO N
H
O R
CH3
Type(XI) R=Aryl
 
      Indazole derivatives of type(XI) have been prepared by the reaction of 
cyclohexenones of type(IX/X) with hydrazine hydrate. 
 
[B]  STUDIES  ON  SCHIFF’S  BASE  DERIVATIVES 
      The chemistry of schiff’s base containing an active imine linkage has 
assumed importance because of their versatility in the synthesis of many 
heterocyclic compounds. Furthermore, they are also associated with wide 
spectrum of pharmacological activities and industrial applications. The 
schiff’s base are reported to possess antibacterial, antiviral, agrochemical and 
diuretic activities. They have been found to be applicable for photosensitive 
materials, polymerization catalysts fluorescents brightening agents, pigments 
etc. With a view to supplement these valid observations, it was contemplated 
to synthesize some novel schiff’s base derivatives using 4-(p-Chlorobenzylox- 
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y)-3-methoxybenzaldehyde with better biological activities which have been 
described as under. 
 
PART - I: STUDIES ON SCHIFF’S BASE 
      Schiff’s base derivatives are endowed with different therapeutic activities 
such as antibacterial, analgesic, anthelmintic, antiinflammatory, 
antitubercular, etc.  These valid observations led us to synthesize some novel 
schiff’s base derivatives which have been described as under. 
 
SECTION-I : Synthesis and biological evaluation of  N-Aryl-1,-4-(p-
chlorobenzyloxy)-3-methoxyphenyl-1-yl-azomethines 
                
                  
N
O
O
CH3
Cl
R
Type (XII)      R=Aryl
 
      The Schiff’s base derivatives of type (XII) have been synthesized by the 
reaction of 4-(p-Chlorobenzyloxy)-3-methoxybenzaldehyde with different 
aromatic amines in presence of glacial acetic acid. 
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PART - II : STUDIES ON AMINE 
      Amine derivatives shows variety of biological activity such as anti-
inflammatory, CNS depressant, anticonvulsant, etc. Due to the wide range of 
biological activities, it was contemplated to synthesize some novel amine 
derivatives, which have been described as under. 
 
SECTION-I : Synthesis and biological evaluation of 4-(p-                 
Chlorobenzyloxy)-3-methoxy-benzylarylamines 
                   
O
O
CH3
ClNH
R
Type (XIII)      R=Aryl
 
 
      The amine derivatives of type (XIII) have been synthesized by the 
reduction of N-Aryl-1,-4-(p-chlorobenzyloxy)-3-methoxyphenyl-1-yl- 
azomethines  with  sodiumcyanoborohydride. 
 
Characterization 
      The constitution of the synthesized products has been characterized by 
Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectrosco-  
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py and further supported by mass spectrometry. Purity of all the compounds 
has been checked by thin layer chromatography. 
 
In vitro study on multiple biological activities 
      All  the  compounds  have  been  evaluated  for  their antibacterial   
activity  towards  Gram positive  and  Gram  negative bacterial  strains  and  
antifungal  activity  towards  A. niger at a concentration  of  40 µg. The 
biological activity of the synthesised compounds has been compared with 
standard drugs. 
 
 
 
        Signature of Guide                                       Signature of Candidate 
         (Dr. V. R. SHAH)                                     (Kamlesh N. Borkhataria) 
 
 
. 
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INTRODUCTION 
 
SYNTHESIS AND CHARACTERISATION OF THERAPEUTICALLY 
INTERESTED COMPOUNDS 
 
          Research programs for the discovery of new drugs and for improving the evolution 
criteria are under way in many laboratories. In addition knowledge of specific 
constituents of the mycobacterium cell and their biochemical roles has advanced 
consideration in the recent years and may permit a more rational approach to the design 
of new drug action on specific targets. Also, recent improvements in the knowledge of 
the mechanism of action of available drugs and the biochemical mechanism of resistance 
to them may be used as a basis for design new and better weapons to fight the 
mycobacterial diseases. 
          The current environment for discovery and development of new pharmaceutical 
agents could hardly be challenging. Public policies and attitudes are requiring reduction 
in health care expenditures and increase efficiencies, resulting in major health care 
reform in the United States. At the sometime, major diseases remain untreated and 
paradoxically, scientific progress continues with ever increasing acceleration. 
          The last few decades have witnessed massive advances in biochemistry, 
physiology, pharmacology and genetics. This has to a better understanding of working 
the body at the molecular level. This in turn has resulted a much better understanding of 
the structure and function of important drug targets e.g. enzymes and receptors and that 
how drugs can be designed for these targets. 
          Advances in genetics engineering have been used to produce human proteins and 
enzymes in fast growing microbial cells, allowing these molecules to be obtained in far 
greater yields than if they were extracted from human tissue. This makes it easier to study 
these micro molecules and to design drugs that will interact with them. Mapping of 
human DNA through human genome project has immense implications for medicinal 
chemistry. 
          Advances in chemistry have made possible the synthesis of complex molecules. 
Enantiometry is an important process in medicinal chemistry since life is inherently chiral 
and the drug targets within the body are chiral. As such, they can distinguish between the 
enantiomers of a chiral drug, so the use of recemic drug is inherently wasteful, since only 
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one enantiomer is ideally designed to interact with its target. Moreover, the existences of 
the “wrong” enantiomer could create problems if it interacted with a different receptor, 
resulting inside effects. 
          The focus of drug design has switched from structure oriented to target oriented 
research, e.g. development of the antiulcer agent cimetidine. Histamine was the lead 
compound for the project and various strategies were used to find an analog that would 
prevent it fitting its receptor. Once an antagonist was developed, a theory was proposed 
on how it might interact with the histamine receptor at a molecular level. Further analogs 
were then synthesized to test theory and the theory was continuously modified as 
required. 
          In the nineteenth century, chemistry developed as a science, both in terms of 
experimental procedures and scientific theory. Scientist isolated and purified single 
compound from natural extracts. Methods of organic synthesis were developed that 
helped chemists altering structures in a predictable way. 
          The chemists started separating out the various components of ancient positions to 
discover whether a single compound was responsible for the medicinal effect known as 
the active principle. 
          Drugs are chemicals of low molecular weight (~100-500) which interact with 
macromolecular targets to produce a biological response. The biological response may be 
therapeutically useful in the case of medicines or harmful in the case of poisons. Most 
drugs used in medicine are potential poisons if taken in higher doses than recommended. 
          Drugs are classified by their chemical structures. Drugs classified in this way share 
a common structural feature and often share similar pharmacological activity. For 
example, all penicillin’s contain a β-lactum ring and kill bacteria by the same mechanism, 
as a result, this classification can sometimes be useful in medicinal chemistry. However, 
it is not foolproof. Sulfonamides have a similar structure and are mostly antibacterial. 
However some sulfonamides are useful in the treatment of diabetes. Similarly all steroids 
have a tetracyclic structure, but the pharmacological effect of different steroids can be 
quite different e.g. testosterone is a sex hormone. Spironolactone is a diuretic. 
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          Finally, classifying drugs according to their molecular target is the most useful 
classification as far as medicinal chemist is concerned, since it allows a rational 
comparison of the structure involved. 
          Any drug must ideally have a broad spectrum of activity, with a rapid bactericidal 
action. Some bacteria produce enzymes that can inactivate or modify antibiotics action. 
Some bacteria produce enzymes that can inactivate or modify antibiotics and 
insusceptibility of a drug to such degradation or modification could result in its playing 
an important part in therapy. Likewise, some bacteria possess an outer membrane that 
acts as a permeability barrier to the entry of some, but not all, antibiotics. Drugs that can 
readily penetrate this barrier might again be expected to be of possible clinical 
importance. 
          The modern concept of drug discovery supported in 1933 by Gerhand Dumagk 
with his finding of prontosil red a compound responsible for the antibacterial activity. In 
1939 Florey and Chain investigate penicillin-G which was discovered ten years earlier by 
Alexander Fleming. 
          The word drug is described from the french word drogue which mean a dry herb. 
According to WHO a drug may be define as “Any substance or product which is used or 
intended to be used for modifying on exploring physiological system or pathological 
status for the benefit of the recipient.” There are two main division of medicinal 
chemistry. The first chemotherapy, concern with the treatment of infections, parasite or 
malignant disease by chemical agents, usually substance that shows selective toxicity 
towards the pathogen. 
          During the period of 1940 to 1960 a large number of important drugs have been 
introduced and this period is regarded as “Golden Period” of new drug discovery.  
          During the period of 1930-1950 there was an urgent need for new drugs for treat 
diseases which had a high mortality rate, there was only limited appreciation of the 
hazard. Such drugs might present and toxicological studies before cinical trials were 
fairly radimenting proving the proverb “Necessity is the mother invention”, during the 
dacade of 30 and 40s. 
          Taking in view of the applicability of heterocyclic compounds, we have undertaken 
the preparation of heterocycles bearing pyrazole nucleus. The placements of a wide 
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variety of substituents of these nuclei have been designed in order to evaluate the 
synthesised products for their pharmacological profile against several strains of bacteria 
and fungi. 
 
AIM AND OBJECTIVES 
 
          In the pharmaceutical field, these have always been and will continue to be a need 
for new and novel chemical inhibitors of biological function. Our efforts are focused on 
the introduction of chemical diversity in the molecular from work in order to synthesizing 
pharmacologically interesting compound of widely different composition. 
          During the course of our research work, looking to the application of heterocyclic 
compounds, several entities have been designed, generated and characterized using 
spectral studies. The details are as under. 
1.   To synthesize therapeutically active compounds like pyrazolines, cyanopyridines,     
pyrimidines, indazoles, schiff’s bases and arylamines bearing chlorobenzyloxy 
moiety. 
2.   To generate several intermediates like chalcones, cyclohexenones bearing chloro-
benzyloxy acetophenone moiety. 
3.    To characterize these products for structure elucidation using several spectroscopic   
techniques like IR, PMR and Mass spectral studies. 
4.     To assess the reaction and purity of the compounds were done by TLC. 
5.    For better drug potential these products were evaluated against different strains of  
bacteria and fungi. 
 
          Taking in to consideration the applicability of heterocyclic compounds, the 
placement of variety of substituent in these nuclei has been designed in order to evaluate 
the synthesized products for their better pharmaceutical profile. 
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[A] STUDIES ON CHALCONE DERIVATIVES 
 
INTRODUCTION 
 
The term “chalcone” was first coined by Kotanecki, who did pioneering work 
in the synthesis of natural coloring compounds. They are characterized by their 
possession of a C6(A)-CO-CH=CH-C6(B) structure in which two aromatic ring A and B 
are linked by an aliphatic three carbon chain. 
      
          
O
B
(I)
A
 
 
 Chalcones are phenyl styryl ketones containing reactive keto-ethylinic group 
(-CO-CH=CH-). They are also known as benzalacetophenones or benzylidene 
acetophenones, the alternatively names given to chalcone are β-phenyl acrylophenone, α-
oxo- α ,β-diphenyl- β-propylene and α-phenyl-β-benzoyl ethylenes. 
 
SYNTHETIC ASPECT 
 
A variety of methods are available for the synthesis of chalcones. The most 
convenient method is the one that involves the Clasien-Schmidt condensation of 
equimolar quantities of aryl methyl ketones with aryl aldehyde in the presence of 
alcoholic alkali.1-3 Various condensing agents used are alkali of different strength,4,5 
Hydrogen chloride6,7, Phosphorous oxychloride8, Piperidine, Anhydrous 
aluminiumchloride10, Boron trifluoride11, Borax12, Aminoacids13, Perchloric acid14 etc. 
 
MECHANISM 
 
The following two mechanisms have been suggested for the synthesis of 
chalcones. 
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REACTIVITY OF CHALCONES 
 
The chalcones have been found to be useful for the synthesis of many heterocyclic 
compounds. 
 
1. Chalcone contain a Keto-Ethylenic group and therefore reactive towards a number of 
reagents yielding various heterocyclic compounds exhibiting significant biological 
activities viz. pyrazolines15, cyanopyridines16,cyanopyrans17, cyanopyridones18, 
pyrimidines19-21, isoxazoles22,indazoles23etc. 
 
2. Chalcones are intermediate compounds for the synthesis of some naturally occuring 
heterocyclic compounds like flavones, flavanones, flavanoids, dihydroflavanols, benzal 
coumarinones, anthocyanins etc. 
 
3. The structure of some naturally occurring pigments like chrysin, galangin, kaempferol 
and quercetrol were established by their synthesis from suitably substituted chalcones.24 
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4. They have been useful in providing structure of some natural products like 
cyanomulcurin25, eviodictoyl26, hemlocktanin27, narighenin28, plioretin29etc. 
 
5. Chalcones are also useful for the detection of Fe(II)30 and Ca(II)31 ions in presence of 
Ba and Sr as it reacts with number of metal ions. Trihydroxy chalcones were used as 
analytical reagents for amperometric estimation of copper32and for spectrophotomatric 
study of the germanium.33 
 
6. The chalcones are natural biocides34,35and are well-known key intermediate in the 
synthesis of heterocyclic compounds possessing biodynamic behaviour.36-38 
 
7. Chalcone and their derivatives are also found to be applicable as lightstabilizing 
agent39, sweetening agent40, oganic brightening agent, photosensitive material, 
polymerisation catalyst, scintillators as well as fluorescentwhitening agent. 
 
THERAPEUTIC IMPORTANCE 
 
Chalcones derivatives have been found to possess wide range of therapeutic activities as 
shown below. 
 
1. Antitumor41,42 
 
2. Antispasmodic43 
 
3. Antiulcer44,45 
 
4. Anthelmintics46,47 
 
5. Bactericidal48,49 
 
6. Cardiovascular50 
 
7. Fungicidal51-53 
 
8. Germicidal54 
 
9. Herbicidal55 
 
10. Insecticidal56-58 
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11. Antiallergic59 
 
12. Anticancer60,61 
 
13. Antiinflammatory62,63 
 
14. Antimalarial64,65 
 
15. Antitubercular66,67 
 
16. Antiviral68 
 
          Chalcones are potential biocides, because some naturally occurring antibiotics69 
and amino chalcones70,71 probably owe their biological activity in the presence of the α,β-
unsaturated carbonyl group. Nelson G. L. et al.72 synthesized the analogs of prostaglandin 
(II). 
 
                                          
O R1
O
R
(II)  
 
 
           The compound 4-[1-Oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-1-piperazine 
acetic acid ethyl ester (III) has been marketed under the name of ‘Cinepazet’ used as 
vasodilator. The other 5-Methoxy-2-methyl-1-(1-oxo-7-phenyl)-1H-indole-3-acetic acid 
(IV) has been marketed under the name of ‘Cinmetacin’ and useful as anti-inflammatory 
drug. 
 
       
OCH3
H3CO
H3CO
N
O
N COOCH2CH3
(III)  
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H3CO
N
COOH
CH3
O
(IV)  
 
          Some dihydrochalcones are well known for their sweetening property 73,74 and 
appear to be non-nutritive sweeteners. A dihydrochalcone ‘Uvaretin’ from Uvaria 
acuminate has shown antitumor activity75 in lymphocytic leukemia test. V. K. Ahluwalia 
et al.76 have noted that 5-Cinnamoylchalcones (V) have shown good antibacterial 
activity. 
 
R1
R
O
OHOH
OH
O
R
R1
(V)  
 
           Chalcones have served as starting material for several synthetic manipulations and 
a versatile synthon in organic synthesis. Moreover, Khatib S. et a1.77 synthesized some 
novel chalcones as potent tyrosinase inhibitors(VI). Ko H. H. et al. 78 have prepared 
chalcones and found active against potent inhibition of platelet aggregation. Ziegler H. L. 
et al.79 reported some novel chalcones as antiparasitic.  
 
OH
OH
O
OH
OH
(VI)  
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          Go M. L. et al.80 have described the synthesis and biological activities of chalcones 
as antiplasmodial. Xue C. X. et al.81 synthesized and reported chalcones as antimalarial 
agents. Fu Y. et al.82 have synthesized Licochalcone-A. Furthermore, Alcaraz M. J. et 
al.83 have described the role of nuclear factor-kappaB and hemeoxygenase-1 in the 
mechanism of action of an anti-inflammatory chalcone derivative in RAW 264.7 cells. 
Nerya O. et al.84 have prepared chalcones as potent tyrosinase inhibitors. Sabzevari O. et 
al.85 have constructed some new chalcone derivatives as molecular cytotoxic mechanisms 
for anticancer activity (VII). 
 
O
OMe
OMe
OH
O
(VII)  
 
          Recently, Ban H. S. et al.86 synthesized some novel chalcones as inhibition of 
lipopolysaccharide-induced expression of inducible nitric oxide synthesis and tumor 
necrosis factor-α by 2'-hydroxychalcone derivatives in RAW 264.7 cells. Hollosy F. et 
al.87 have prepared some new chalcones as plant-derived protein tyrosine kinase 
inhibitors as anticancer agents.  
Chalcones have been proved to be an important intermediate for the 
synthesis of many heterocyclic compounds in organic chemistry. These facts pormpted us 
to synthesize some novel chalcone derivatives bearing 1-[4-(Methylsulfonyl) 
phenyl]ethanone. In order to achiving better therapeutic agents, we have undertaken the 
synthesis of chalcones and its derivatives, which have been described in following part. 
 
PART - I : STUDIES ON PYRAZOLINES 
 
PART - II : STUDIES ON CYANOPYRIDINES 
 
PART - III : STUDIES ON PYRIMIDINES 
 
PART - IV : STUDIES ON INDAZOLES 
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PART-I : STUDIES ON PYRAZOLINES 
 
INTRODUCTION 
 
  Amongst nitrogen containing five membered heterocycles, pyrazolines have 
proved to be the most useful framework for biological activities, Pyrazolines have 
attracted attention of medicinal chemists for both with regard to heterocyclic chemistry 
and the pharmacological activities associated with them. In 1967 Jacobe, reviewed the 
chemistry of pyrazolines, which have been studied extensively for their biodynamic 
behaviour88 and industrial applications.89 
 
N
H
N
(I)
 
 
SYNTHETIC ASPECT: 
 
               Different methods for the preparation of 2-pyrazoline derivatives documented in 
literature are as follows. 
 
1. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile and the N-
aryl maleimides yields the corresponding pyrazolines90 
2. Epoxidation of chalcones i.e. epoxy ketones which reacted with hydrazine and phenyl 
hydrazine to give pyrazolines91. Furthermore, B. Gyassi et al.92 investigated the one pot 
synthesis of some pyrazolines in dry media under microwave irradiation. S. Paul et al.93 
and Dandia Anshu et al.94 have also described the microwave assisted synthesis of 2-
Pyrazolines. 
3. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones with 
hydrazine hydrate95 
4. 2-Pyrazolines can also be prepared by the condensation of chalcone dibromide with 
hydrazine96 
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5. 2-Pyrazolines can be  synthesised by the cycloaddition of diazomethane with 
substituted chalcones.97 
 
MECHANISM 
 
         The following mechanism seems to be operable for the condensation of chalcones 
with hydrazine hydrate.98 
 
R1 R
O
NH2NHR
2
NH+
CH-
C+
O-
NH2R
2
RR1 (i) Proton transfer
(ii) Ketonization
N O
NH2R
2
RR
1
Intramolecular neucleophilic attack N N
H
R
OH
R2
R1
N N
R
R2
R1
-H2O
 
 
              Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl 
system forms species, in which the -ve charge is mainly accomodated by the 
electronegative oxygen attom.  
              Proton transfer from the nitrogen to -ve oxygen produces an intermediate enol 
which simultaneously ketonises to ketoamine. Another intramolecular nucleophilic attack 
by the primary amino group of ketoamine on its carbonyl carbon followed by proton 
transfer from nitrogen to oxygen leads ultimately to carbonyl amine. The later with a 
hydroxyl group and amino group on the same carbon lose water molecule to yield the 
pyrazolines. 
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THERAPEUTIC IMPORTANCE 
 
             From the literature survey, it was revealed that 2-Pyrazolines are better 
therapeutic agents some of them are as shown bellow.   
 
1. Antiallergic99 
 
2. Anticonvulsant100,101 
 
3. Antidiabetic102 
 
4. Antiimplantation103 
 
5. Antiinflammatory104 
 
6. Antitumor105 
 
7. Antineoplastic106 
 
8. Antimicrobial107 
 
9. Analgesic108,109 
 
10. Bactericidal110,111 
 
11. Cardiovascular112 
 
12. Diuretic113 
 
13. Fungicidal114 
 
14. Herbicidal115 
 
15. Hypoglycemic116 
 
16. Insecticidal117 
 
17. Tranquilizer118 
 
            
 
               Moreover F. Manna and co-worker119 have described 1-Acetyl-5-(2' 
bromophenyl)-4,5-dihydro-3-(2'-hydroxyphenyl)-1H-pyrazoline and its derivatives which 
acts as potent antiinflammatory, analgesic and antipyratic agents. Udupi R. H. and Bhatt 
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A. R.120 have reported the synthesis and biological activity of Mannich bases of certain 
1,2-Pyrazolines. Nugent Richard121 investigated pyrazolines bis phosphonate ester as 
novel antiinflammatory and antiarthritic agent. Fuche Rainer et al.122 have prepared some 
new 1H-Pyrazoline derivatives and reported them as pesticides. Furthermore, Tsubai et 
al.123 have synthesized some new Phenylcarbamoyl pyrazolines as an insecticide and at 
40% concentration shows 100% mortality of spodopetra litura larve after seven drops.  
               
               Shulabh Sharma et al.124 have synthesized pyrazolines and tested their 
antiinflammatory activity (II).Ashok Kumar et al.125 have synthesized pyrazolines as 
anticonvulsant agents (III). Maurer Fritz et al.126 have synthesized pyrazoles and screened 
for their pesticidal activity.  
 
     
NH
N
H
S
N
NH
N
N
COCH3R(II)
NH
N
H
O
O
S
N N COCH3
OCH3
(III)
 
 
                   E. Palaska et al.127 have prepared 3,5-Diphenyl-2-pyrazolines (IV) and cited 
their antidepressant activity. B. Shivarama et al.128,129 have synthesized pyrazolines as 
antibacterial agents. Hiremath S. P. et al.130 have reported pyrazolines as analgesics, 
antiinflammatory and antimicrobial agents. Malhotra V. et al.131 have synthesized new 
pyrazolines as  cardiovascular agents (V). 
 
N
H
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           Moreover, T. M. Stavenson et al.132 have also investigated N-substituted 
pyrazoline type insecticides. Tanka Katsohori 133 have patented pyrazoline derivatives as 
herbicides and Johannes et al.134 as insecticides. Moritaz Z. and Hadol135 investigated a 
semi emperial molecular orbital study on the reaction of Aminopyrazolinyl azodye with 
single molecular oxygen. Shivananda M. K. and co-workers136 have prepared substituted 
pyrazolines and reported their antibacterial activity. Almstead J. et al.137 have prepared 
pyrazolines as vascularization agents. Guniz Kacukguzel et al.138 have synthesized 
pyrazolines as a antimicrobial and anticonvulsant agents. Gulhan T. Z. and co-workers139 
have prepared pyrazolines as a hypotensive agent. S. S. Sonarc et al.140 have synthesized 
3-(2-Acetoxy-4-methoxyphenyl)-5-(substituted phenyl)-pyrazolines and tested their 
antimicrobial activity. H. H. Parekh141 et al. have also synthesized some new pyrazolines 
as an antimicrobial agent. G. N. Mishrika et al.142 have also prepared 2-pyrazolines of 
salicyclic acid possessing antimicrobial properties. Tunfawy Atif and co-workers143 have 
patented 3-Methyl-4'-(substituted phenylazo)-pyrazol-5-ones as antibacterial agents. 
 Thus, significant biological properties associated with pyrazoline derivatives  
have aroused considerable interest  to design the compounds with better drug potentials 
and to study their pharmacological profile, which have been described as under. 
 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-[4’-
(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-PROPENO- 
NES 
 
SECTION-II: SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ACETYL-
3-ARYL-5-[4’-(P-CHLOROBENZYLOXY)-3’-METHOXYPHEN-
YL]-4,5-DIHYDRO-1H-PYRAZOLES  
 
SECTION-III: SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-
[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1-(p-FL- 
UOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOLES 
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SECTION-I 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-PROPENONES 
 
           Chalcone derivatives occupy a unique place in the field of medicinal chemistry 
due to wide range of biological activities exhibited by them, prompted by these facts, the 
preparation of chalcones of type (I) have been carried out. 
           The chalcone derivatives of Type (I) have been synthesized by the reaction of 4-
(p-Chlorobenzyloxy)-3-methoxybenzaldehyde with different acetophenone in presence of 
40% NaOH.  
    
O
O
CH3
Cl
O
RType(I)
R=Aryl
CH3O
O
O
CH3
Cl
RCOCH3
Alkali
 
 
 
               The structure elucidation of synthesized compounds has been done on the basis 
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry.Purity of all compounds have been checked by 
thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs.  
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                        REACTION SCHEME 
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IR SPECTRAL STUDIES OF 1-(p-METHOXYPHENYL)-3-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-PROPENONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2951.45 2975-2950 A 
-CH3 C-H str. (sym.) 2874.91 2880-2860 “ 
 C-H def. (asym.) 1466.61 1470-1435 “ 
Aromatic C-H str. 3061.5 3090-3030 “ 
 C=C str. 1506.71 1540-1480 “ 
 C-H i.p. (def.) 1163.04 1177-1027 “ 
 C-H o.o.p. (def.) 818.37 835-810 “ 
Methoxy C-O str. 1260.81 1260-1200 “ 
Halide C-Cl str. 639.44 800-600 “ 
ketone C=O str. 1672.29 1700-1640 “ 
Ether Ar-O-C str. 1235.34 1260-1200 “ 
α,β unsaturated C=C str. 1583.95 1580-1550 “ 
O
O CH3
Cl
O
O CH3
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NMR SPECTRAL STUDIES OF 1-(p-METHOXYPHENYL)-3-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-PROPENONE 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment of 
proton(s) 
1.  3.88 s 3 -- 7” 
2.  3.94 s 3 -- 14’ 
3.  5.15 s 2 -- 7’ 
4.  6.86 d 1 7.97 2 
 5. 
 6.96-8.03 
m 
 11 -- 
2’,5’,6’,9’,10’,
12’,13’,2”,3” 
,5”,6” 
6. 7.73 d 1 15.56 3 
Total No. of protons  21  
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3
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MASS SPECTRUL STUDIES OF 1-(p-METHOXYPHENYL)-3-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-PROPENONE 
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MASS FRAGMENTATION 
M/z : 394.13
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ANTIMICROBIAL ACTIVITY 
 
Method                                              :            Cup –Plate146 
Gram positive bacteria                      :            Bacillus subtillis 
                                                                        Bacillus coccus 
Gram negative bacteria                     :             Escherichia coli 
                                                                        Proteus vulgaris 
Fungi                                                 :             Aspergillus niger 
Concentration                                    :             40µg 
Solvent                                              :             Dimethyl formamide 
Standard drugs                                  :             Ampicillin, Amoxicillin, Norfloxacin,                                       
                                                                        Benzyl penicillin, Griseofulvin. 
          The antimicrobial activity was compared with standard drugs like  Ampicillin, 
Amoxicillin, Norfloxacin, Benzyl penicillin and antifungal activity was compared with  
Griseofulvin. The zones of inhibition were measured in mm. 
 
ANTIMICROBIAL ACTIVITY 
 
          The purified products were screened for their antimicrobial activity using Cup-
Plate146 agar diffusion method. The control was with 0.04ml (40µg) of sample in DMSO. 
In case of antibacterial activity, the plates were incubated at 37oC for 24 hrs and for 
antifungal activity the plates were incubated at 30 oC for 48 hrs. 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-PROPENONES 
  
(A)   Synthesis of 4-(p-Chlorobenzyloxy)-3-methoxybenzaldehyde 
          The solution of Vaniline(1.53g, 0.01M) in DMF ( 7.7ml) was heated at 50-550C    
with 4-chlorobenzyl chloride(1.75g, 0.01) and K2CO3(2.76gm, 0.02) for 5 hrs, after 5 hrs 
product was precipitated by water addition. The separated solid was filtered and leached 
in Methanol.Yield 90%, m.p.110 o C. 
 
 (B)   Synthesis of 1-(4-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphe- 
nyl]-propenone 
          To the solution of 4-(p-Chlorobenzyloxy)-3-methoxybenzaldehyde(2.76g, 0.01M) 
in Methanol(14ml) was heated at 50-550C  with  4-Methoxyacetophenone(1.8gm, 
0.012M) and NaOH(0.08g,0.002M) for 12 hrs, after 12 hrs product was filtered and 
recrystallized in Ethanol,.Yield 80%, m.p 140o C, (C24 H21ClO4; Required: C,70.50; 
H,5.18; Found: C, 69.92 ; H, 5.15;%)  Similarly, other 1-Aryl-3-[4’-(p-chlorobenzyloxy)-
3’-methoxyphenyl]-propenones were prepared. The physical data are recorded in Table 
No.1 
 
(C) Biological evaluation of 1-Aryl-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
propenones 
           All the compounds have been screened for antibacterial and antifungal activity as 
described under. 
 
ANTIMICROBIAL ACTIVITY 
           It was carried out by cup-plate146 diffusion method which has been described as 
under.   
(a) Antibacterial activity146 
 
          The purified products were screened for their antibacterial activity using cup-plate 
agar diffusion method. The nutrient agar broth prepared by the usual method was 
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inoculated aseptically with 0.5 ml of 24 hrs. old subcultures of Bacillus subtillis, Bacillus 
Coccus, Escherichia coli, Proteus Vulgaris in separate conical flasks at 35-40o C and 
mixed well by gentle shaking. About 25 ml content of the flask was poured and evenly 
spreaded in a petridish (13 cm diameter) and allowed to set for 2 hrs. The cups (10 mm 
diameter) were formed by the help of borer in agar medium and filled with 0.04ml (40µg) 
solution of sample in DMF. The plates were incubated at 37o C for 24 hrs. and the control 
was also maintained with 0.04ml of DMF in a similar manner and the zone of inhibition 
of the bacterial growth was measured  in millimeter  and recorded in Graphical  Chart 
No. 1 
(b) Antifungal activity146 
 
          Aspergillus niger  was employed for testing antifungal activity using cup-plate agar 
diffusion method. The culture was maintained on sabourauds agar slants sterilized 
sabourauds agar medium was inoculated with 72 hrs. Add 0.5ml suspension of fungal 
spores in a separate flask. About 25ml of the inoculated medium was evenly spreaded in 
a petridish (13cm diameter) and allowed to set for 2 hrs. The cups (10mm diameter) were 
punched. The plates were incubated at 30o C for 48 hrs. After the completion of 
incubation period, the zone of inhibition of growth in the form of diameter in mm was 
measured. Along the test solution in each petridish one cup was filled up with solvent, 
which acts as control. The zone of inhibition of test solution are recorded in Graphical 
Chart No. 1 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among chalcone derivatives tested compounds 
1a,1h,1i and 1k showed greater degree of antibacterial activity against B.coccus. 
However, the compounds 1a,1b,1h and 1j showed greater degree of antibacterial activity 
against B.subtilis. The compounds 1c,1d,1h and 1i showed greater degree of antibacterial 
activity against E.coli. However, the compounds 1b,1e,1g and 1j showed greater degree 
of antibacterial activity against P.vulgaris. 
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Antifungal activity 
           The screening data indicated that among chalcone derivatives tested compounds 
1i,1l showed greater degree of antifungal activity against  A.niger. 
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TABLE NO. 1: PHYSICAL CONSTANT OF 1-ARYL-3-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-
PROPENONES  
Comp. 
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular 
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent  
System  
10 
Calcd.
8
Found 
9
1a -C6H5 C23H19ClO3 378.50 145 0.56 50 -- -- S1 
1b -4-OCH3-C6H4 C24H21ClO4 408.50 140 0.46 56 -- -- S2 
1c -4-Cl-C6H4 C23H18Cl2O3 413.00 155 0.40 74 -- -- S2 
1d -2,4-(Cl)2-C6H3 C23H17Cl3O3 447.50 165 0.38 42 -- -- S2 
1e -4-OH-C6H4 C23H19ClO4 394.50 170 0.36 60 -- -- S2 
1f -4-Br-C6H4 C23H18BrClO3 457.50 180 0.58 55 -- -- S1 
1g -4-NO2-C6H4 C23H18ClNO5 423.50 190 0.34 68 3.30 3.32 S2 
1h -4-NH2-C6H4 C23H20ClNO3 393.50 153 0.37 66 3.56 3.51 S2 
1i -2-OH-C6H4 C23H19ClO4 394.50 178 0.32 58 -- -- S1 
1j -4-CH3-C6H4 C24H21ClO3 392.50 154 0.62 45 -- -- S1 
1k -2,4-(OCH3)2-C6H3 C25H23ClO5 438.50 142 0.52 80 -- -- S1 
1l -4-(O-CH2-C6H5)-C6H4 C30H25ClO4 484.50 174 0.74 57 -- -- S1 
TLC Solvent system, S1: Methanol: Dichloromethane (0.4:9.6) ; S2 : Ethyl acetate : Hexane (4.0:6.0) 
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GRAPHICAL CHART NO.1: ANTIMICROBIAL ACTIVITY OF 1-ARYL-3-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-PROPENONES 
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B.coccus 15 14 11 14 12 12 12 15 17 15 17 10 20 21 18 20 0
B.subtilis 14 15 13 14 12 9 14 17 12 18 14 14 24 24 17 18 0
E.coli 14 12 15 16 14 11 12 14 17 14 12 11 22 25 24 18 0
P.vulgaris 12 16 13 11 17 12 15 15 17 13 10 12 21 25 25 15 0
A.niger 14 12 10 14 17 15 16 15 16 13 14 18 0 0 0 0 24
1a 1b 1c 1d 1e 1f 1g 1h 1i 1j 1k 1l Ampicillin
Amoxi
cillin
Norflo
xacin
Benzyl 
Penicil
lin
Griseo
fulvin
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SECTION – II 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ACETYL-3-ARYL-5-[4’-
(P-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-4,5-DIHYDRO-1H-PYRA-
ZOLES  
          The broad spectrums of pharmacological properties have been demonstrated by the 
pyrazoline nucleus. Inspired by these facts, new pyrazoline derivatives of Type (II) have 
been investigated. The 1-Aryl-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-propenones  
type-(I) on treatment with hydrazine hydrate in acetic acid yielded 1-Acetyl-3-aryl-5-[4’-
(p-chlorobenzyloxy)-3’-methoxyphenyl]-4,5-dihydro-1H-pyrazoles  derivatives of  type 
(II).  
 
              
NH2NH2.H2O
gla. aceticacid
N N
O
CH3
O
Cl
O
CH3
R
O
O
CH3
Cl
O
R
Type(I) Type(II) R=Aryl 
 
          The structure elucidation of synthesized compounds has been done on the basis of 
Elemental analysis, Infrared spectroscopy, 1H Nuclear Magnetic Resonance spectroscopy 
and further supported by Mass spectrometry.Purity of all compounds have been checked 
by thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs. 
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O
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Cl
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R=Aryl
N N
O
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Cl
O
CH3
Type(II)
NH2NH2.H2O
gla. aceticacid
REACTION SCHEME
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IR SPECTRAL STUDIES OF 1-ACETYL-3-(p-METHOXYPHENYL)-5-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-4,5-DIHYDRO-1H-PYRAZO- 
LE  
 
 
 
 
 
 
 
 
 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2959.81 2975-2950 A 
-CH3 C-H def. (asym.) 1458.73 1470-1435 “ 
Aromatic C-H str. 3035.45 3090-3030 “ 
 C=C str. 1517.78 1540-1480 “ 
 C-H i.p. (def.) 1097.70 1125-1090 “ 
 C-H o.o.p. (def.) 835.57 835-810 “ 
Pyrazoline C=N str. 1608.89 1612-1593 “ 
 C=O str. 1671.52 1700-1612 “ 
Methoxy C-O str. 1242.41 1260-1200 “ 
Halide C-Cl str. 793.68 800-600 “ 
Ether Ar-O-C str. 1255.10 1260-1200 “ 
 
N N
O
CH3O
Cl
CH3
O
O
CH3
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NMR SPECTRAL STUDIES OF 1-ACETYL-3-(p-METHOXYPHENYL)-5-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-4,5-DIHYDRO-1H-PYRAZO- 
LE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1. 2.40 t 3 -- 7 
2. 3.12 dd 1 17.53 4a 
3. 3.68 dd 1 17.53 4b 
4. 3.85 s 6 -- 7’,7” 
5. 5.06 s 2 -- 8’ 
6. 5.51 dd 1 -- 5 
 
7. 6.68-7.70 m 11 -- 
2’,3’,6’,10’, 
11’,13’,14’2”
,3”,5”,6” 
Total No. of protons 25 
N
O
CH3O
Cl
O
CH3 N
CH3O
2
3451'
2'3'4'
5'
6'
7'
8' 9' 10'
11'
12'
13'
14'
1" 2"
3"
4"
5"
6"
7"
16
7
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MASS SPECTRAL STUDIES OF 1-ACETYL-3-(p-METHOXYPHENYL)-5-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-4,5-DIHYDRO-1H-PYRAZOLE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N N
O
CH3O
Cl
CH3
O
O
CH3
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MASS FRAGMENTATION 
M/z : 396.13
M/z : 262.07
M/z : 138.06
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M/z : 112.0M/z : 142.1
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ACETYL-3-ARYL-5-[4’-
(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-4,5-DIHYDRO-1H-PYRA- 
ZOLES   
(A) Synthesis of 1-(4-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]- 
propenone 
     See [A],Part-I, Section-I (B). 
 
(B) Synthesis of 1-Acetyl-3-(4-methoxyphenyl)-5-[4’-(p-chlorobenzyloxy)-3’- metho- 
xyphenyl]-4, 5-dihydro-1H-pyrazole 
          A mixture of 1-(4-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
propenone (4.08gm, 0.01M)   in glacial acetic acid (20ml) and hydrazine hydrate (2.42ml, 
0.05M) was refluxed for 8 hrs. The product was isolated by water addition, filtered and 
crystallized from ethanol. Yield 56%, m.p. 120o C, (C26 H25ClN2O4; Required: C, 67.17; 
H,5.42; N,6.03; Found: C, 68.12 ; H, 5.15; N,5.93 %) 
           Similarly, other 1-Acetyl-3-aryl-5-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
4,5-dihydro-1H-pyrazoles  were prepared. The physical data are recorded in Table No.2 
 
(C) Biological evaluation of 1-Acetyl-3-aryl-5-[4’-(p-chlorobenzyloxy)-3’-methoxy- 
phenyl]-4, 5-dihydro-1H-pyrazoles 
         Antimicrobial testing was carried out as described in [A].Part-I Section-I(C). The 
zones of inhibition of test solutions are recorded in Graphical Chart No.2 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Acetyl pyrazoline derivatives tested 
compounds 2a,2d,2k and 2l showed greater degree of antibacterial activity against 
B.coccus. However, the compounds 2a,2e,2j and 2l showed greater degree of 
antibacterial activity against B.subtilis. The compounds 2b,2c,2e  and 2g showed greater 
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degree of antibacterial activity against E.coli. However, the compounds 2c,2d,2g and 2h 
showed greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Acetyl pyrazoline derivatives tested 
compounds 2b,2c,2f and 2i showed greater degree of antifungal activity against  A.niger. 
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TABLE NO.2: PHYSICAL CONSTANT OF 1-ACETYL-3-ARYL-5-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-4,5-DIHYDRO-1H-PYRAZOLES   
Comp. 
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular 
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent 
System 
10 
Calcd. 
8
Found
9
2a -C6H5 C25H23ClN2O3 434.50 130 0.46 66 6.44 6.41 S1 
2b -4-OCH3-C6H4 C26H25ClN2O4 464.50 120 0.42 56 6.03 6.05 S1 
2c -4-Cl-C6H4 C25H22Cl2N2O3 469.00 150 0.36 55 5.97 6.01 S2 
2d -2,4-(Cl)2-C6H3 C25H21Cl3N2O3 503.50 160 0.45 74 5.56 5.60 S1 
2e -4-OH-C6H4 C25H23ClN2O4 450.50 180 0.38 65 6.21 6.30 S1 
2f -4-Br-C6H4 C25H22BrClN2O3 513.50 188 0.60 54 5.45 5.48 S1 
2g -4-NO2-C6H4 C25H22ClN3O5 479.50 200 0.55 42 8.76 8.80 S2 
2h -4-NH2-C6H4 C25H24ClN3O3 449.50 165 0.45 75 9.34 9.30 S2 
2i -2-OH-C6H4 C25H23ClN2O4 450.50 185 0.36 63 6.21 6.20 S2 
2j -4-CH3-C6H4 C26H25ClN2O3 448.50 152 0.55 56 6.24 6.30 S1 
2k -2,4-(OCH3)2-C6H3 C27H27ClN2O5 494.50 136 0.63 67 5.66 5.70 S1 
2l -4-(O-CH2-C6H5)-C6H4 C32H29ClN2O4 541.50 202 0.55 6 5.18 5.21 S1 
TLC Solvent system : S1: Methanol:Dichloromethane(0.4:9.6); S2 : Ethyl acetate : Hexane(40:60) 
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GRAPHICAL CHART NO. 2 : ANTIMICROBIAL ACTIVITY OF 1-ACETYL-3-ARYL-5-[4’-(p-CHLOROBENZYLOXY)-
3’-METHOXYPHENYL]-4,5-DIHYDRO-1H-PYRAZOLES   
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B.coccus 20 15 16 19 16 16 15 16 14 19 19 22 20 21 18 20 0
B.subtilis 21 19 17 15 21 18 19 17 12 20 16 21 24 24 17 18 0
E.coli 18 20 19 17 20 12 23 19 19 15 18 19 22 25 24 18 0
P.vulgaris 19 19 21 20 18 19 20 20 20 12 20 18 21 25 25 15 0
A.niger 12 21 20 15 19 20 18 19 21 19 14 20 0 0 0 0 24
2a 2b 2c 2d 2e 2f 2g 2h 2i 2j 2k 2l Ampicillin
Amoxi
cillin
Norflo
xacin
Benzyl 
Penicil
lin
Griseo
fulvin
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SECTION–III 
SYNTHESIS AND BIOLOGICAL  EVALUATION OF  3-ARYL-5-[4’-(p-CHLOR- 
OBENZYLOXY)-3’-METHOXYPHENYL]-1-(p-FLUOROPHENYL)-4,5-DIHYD- 
RO-1H-PYRAZOLES 
  
          Therapeutic importance of pyrazolines aroused considerable interest to synthesize 
pyrazolines of type (III) by the cyclocondensation of 1-(p-Methoxyphenyl)-3-[4’-(p 
chlorobenzyloxy)-3’-methoxyphenyl]-propenones of type-(I) with p-Fluoro 
phenylhydrazine in order to study their biodynamic behaviour. 
 
                           
N N
O
Cl
F
R
OCH3
Type (III)
O
O
CH3
Cl
OR
Type(I) R=Aryl
4-F-phenylhydrazine
 
               
 
 
           The structure elucidation of synthesized compounds has been done on the basis of 
Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry. Purity of all the compounds have been checked 
by thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards A.niger  at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs.  
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IR SPECTRAL STUDIES OF 3-(p-METHOXYPHENYL)-5-[4’-(p-CHLOROBEN- 
ZYLOXY)-3’-METHOXYPHENYL]-1-(p-FLUOROPHENYL)-4,5-DIHYDRO-1H-
PYRAZOLE 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2933.39 2975-2950 A 
-CH3 C-H def. (asym.) 1459.11 1470-1435 “ 
Aromatic C-H str. 3052.89 3090-3030 “ 
 C=C str. 1505.56 1540-1480 “ 
 C-H i.p. (def.) 1110.12 1125-1090 “ 
 C-H o.o.p. (def.) 828.28 835-810 “ 
Pyrazoline C=N str. 1609.97 1612-1593 “ 
Methoxy C-O str. 1219.44 1260-1200 “ 
Halide C-Cl str. 624.87 800-600 “ 
Ether Ar-O-C str. 1261.84 1260-1200 “ 
 
 
 
 
N N
O
CH3O
Cl
F
O
CH3
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NMR SPECTRAL STUDIES OF   3-(p-METHOXYPHENYL)-5-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1-(p-FLUOROPHENYL)-4,5-
DIHYDRO-1H-PYRAZOLE 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
No. Chemical 
Shift 
δ ppm 
Multiplicity No. of 
protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1. 3.09 dd 1 17.0 4a 
2. 3.77 dd 1 16.97 4b 
3. 3.81 s 3 -- 7” 
4. 3.83 s 3 -- 7’ 
5. 5.04 dd 1 -- 5 
6. 5.08 s 2 -- 8’ 
7. 6.80-7.65 m 15 -- 
7,11,2’,3’,6’,1
0’,11’,13’,14’
2”,3”,5”,6” 
8,10 
Total No. of protons  26 
N N
O
CH3O
Cl
F
O
CH3 1 2
345
67
8
9 10
11
1'
2'
3'
4'
5'
6'
7'
8' 9' 10'
11'
12'
13'
14'
1" 2"
3"
4"
5"
6"
7"
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MASS SPECTRAL STUDIES OF 3-(p-METHOXYPHENYL)-5-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-
1-(p-FLUOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N N
O CH3O
Cl
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MASS FRAGMENTATION 
M/z : 486.15
M/z : 262.07
M/z : 138.06 M/z : 136.08
M/z : 112.0M/z : 142.1
+
o
+
o
+
o+o
+o
+
o
+
o
[Base peak]
M/z : 422.13
M/z : 70.05
N N
O CH3O
Cl
F
O
H3C
M/z : 392.15
o
o
+
+
N N
O
Cl
F
O
CH3
N N
O CH3OH
F
O
CH3
N
H
N
O CH3O
Cl
O
CH3
CH3
O
Cl
O
CH3
CH3
OH
O
CH3
CH3
O CH3
N
H
N
OH
Cl Cl
O CH3
O
CH M/z :254.32
CH3
O
O
CH3 M/z : 270.36
CH2O
CH3
CH3
M/z :157.23
o
+
o
+
o
+
M/z : 516.99
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1-(p-FLUOROPHENYL)-4,5-
DIHYDRO-1H-PYRAZOLES 
 
(A)  Synthesis of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]   
-propenone 
        See [A],Part-I, Section-I (B). 
 
(B) Synthesis of 3-(p-Methoxyphenyl)-5-[4’-(p-chlorobenzyloxy)-3’-methoxy- 
phenyl]-1-(p-fluorophenyl)-4,5-dihydro-1H-pyrazole 
        A mixture of 1-(4-methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
propenone (4.08g, 0.01M) in methanol (20ml) and p-Fluorophenyl hydrazine (1.26g, 
0.01mol) was refluxed for 8 hrs. The product was isolated and crystallized from ethanol. 
Yield 63%, m.p. 160o C. (C30 H26ClFN2O3; Required: C,69.70; H,5.07; N, 5.42; Found: 
C, 70.1 ; H, 5.10; N,5.50 %)  Similarly, other 3-Aryl-5-[4’-(p-chlorobenzyloxy)-3’-
methoxyphenyl]-1-(p-fluorophenyl)-4,5-dihydro-1H-pyrazoles  were prepared. The 
physical data are recorded in Table No.3 
 
(C) Biological evaluation of 3-Aryl-5-[4’-(p-chlorobenzyloxy)-3’- methoxyphenyl]-1-
(p-fluorophenyl)-4,5-dihydro-1H-pyrazoles 
          Antimicrobial testing were carried out as described in [A], Part-I Section-I(C). The 
zones of inhibition of test solutions are recorded in Graphical Chart No.3 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Phenyl pyrazoline derivatives tested 
compounds 3a,3c,3i and 3k showed greater degree of antibacterial activity against 
B.coccus. However, the compounds 3d,3g,3h and 3i showed greater degree of 
antibacterial activity against B.subtilis. The compounds 3b,3c,3e  and 3j showed greater 
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degree of antibacterial activity against E.coli. However, the compounds 3b,3c,3f and 3l 
showed greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Phenyl pyrazoline derivatives tested 
compounds 3e,3f,3g and 3h showed greater degree of antifungal activity against  A.niger. 
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TABLE NO.3: PHYSICAL CONSTANT OF 3-ARYL-5-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1-(p-
FLUOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOLES 
Comp. 
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular 
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent 
System 
10 Calcd. 8
Found 
9 
3a -C6H5 C29H24ClFN2O2 486.50 170 0.56 55 5.75 5.70 S1 
3b -4-OCH3-C6H4 C30H26ClFN2O3 516.50 160 0.63 52 5.42 5.40 S1 
3c -4-Cl-C6H4 C29H23Cl2FN2O2 521.00 155 0.66 42 5.37 5.30 S1 
3d -2,4-(Cl)2-C6H3 C29H22Cl3FN2O2 555.50 170 0.44 66 5.04 5.00 S2 
3e -4-OH-C6H4 C29H24ClFN2O3 502.50 176 0.40 30 5.57 5.60 S2 
3f -4-Br-C6H4 C29H23BrClFN2O2 565.50 200 0.63 42 4.95 4.90 S1 
3g -4-NO2-C6H4 C29H23ClFN3O4 531.50 210 0.55 71 7.90 7.85 S1 
3h -4-NH2-C6H4 C29H25ClFN3O2 501.50 185 0.50 62 8.37 8.40 S1 
3i -2-OH-C6H4 C29H24ClFN2O3 502.50 163 0.40 64 5.57 5.60 S2 
3j -4-CH3-C6H4 C30H26ClFN2O2 500.50 145 0.56 80 5.59 5.65 S1 
3k -2,4-(OCH3)2-C6H3 C31H28ClFN2O4 547.00 166 0.60 72 5.12 5.15 S1 
3l -4-(O-CH2-C6H5)-C6H4 C36H30ClFN2O3 593.00 189 0.62 40 4.72 4.70 S1 
TLC Solvent system : S1 : Methanol:Dichloromethane(0.4:9.6); S2 : Ethyl acetate : Hexane(4.0:6.0) 
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GRAPHICAL CHART NO. 3 : 3-ARYL-5-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1-(p-FLUOROPHENY- 
L)-4,5-DIHYDRO-1H-PYRAZOLES 
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B.coccus 20 15 16 16 16 16 15 15 18 15 19 16 20 21 18 20 0
B.subtilis 19 19 19 21 21 14 21 21 23 21 14 12 24 24 17 18 0
E.coli 16 22 22 20 22 18 20 16 14 22 12 18 22 25 24 18 0
P.vulgaris 15 21 21 18 15 19 17 14 12 16 19 20 21 25 25 15 0
A.niger 14 12 15 14 20 21 19 21 19 12 18 18 0 0 0 0 24
3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l Ampicillin
Amoxi
cillin
Norflo
xacin
Benzyl 
Penicil
lin
Griseo
fulvin
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PART-II : STUDIES ON CYANOPYRIDINES 
 
INTRODUCTION 
 
          Pyridine is the parent of the series of compounds that is important in 
pharmaceutical, agriculture and industrial chemistry. Among a wide range of pyridines, 
3-cyanopyridines acquired a special attention due to their wide range of therapeutic 
activities. Most derivatives are prepared by manipulation of pyridine and its simple 
homologues in a manner similar to chemistry of the benzenoid chemistry. However the 
simple pyridine compounds are prepared by the cyclization of aliphatic raw materials. 
The pyridine nucleous is found in a large number of commonly used drugs which have 
diverse pharmacological activities. Interests in the synthesis of multicyclic pyridine 
containing compounds have increased in recent years because of their biological and 
pharmacological activities. In our continuation work in the chemistry of pyridine 
nucleous, we have undrtaken the synthesis of derivatives such as 2-Amino-6-aryl-4-[4’-
(p-chlorobenzyloxy)-3’-methoxyphenyl]-3-cyanopyridines via chlacones. 
 
                                            
N
CH3
O
R
O
CH3O
N  
 
 
SYNTHETIC ASPECT: 
 
Preparations of 3-Cyanopyridines have been cited in literature1-6 with different methods. 
1. Samour and co-worker7 have prepared substituted cyanopyridines by the 
condensation of chalcones with malononitrile in presence of ammonium 
acetate. 
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MECHANISM  : The reaction proceeds through conjugate addition of active methylene 
compounds to the α, β-unsaturated system as shown below. 
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THERAPEUTIC IMPORTANCE 
 
         The extensive use of cyanopyridine derivatives have been established in medicine 
due to its antihypertensive, anticholestemic, antidiabetic, antifungal and antibacterial 
properties.Few of them reported as shown below. 
1. Antifungal8 
 
2. Antiepileptic9 
 
3. Antibacterial10 
 
4. Anticonvulsant11 
 
5. Antitubercular12 
 
6. Analgesic13 
 
7. Insecticidal14 
 
8. Antisoriasis15 
 
9. Antihypertensive16 
 
          The synthesis of cyanopyridines are of current interest owing to their enormous 
occurence in biologically active derivatives. Hence, considerable attention has been 
focused on the study of efficient and pharamaceutical important cyanopyridines bearing 
benzimidazole nucleus.  
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          El-Nabawia et al.17 have prepared 2-Amino-3-cyano pyridine derivatives (I) and 
studied their antimicrobial activity. S. Guru et al.18 have synthesized various 
cyanopyridyl derivatives (II) and documented their multiple biological activities. 
          The insecticidal activity of cyanopyridines have been screened by Y. Sasaki19 et al. 
Umed Ten et al.20 have prepared cyanopyridines as agrochemical fungicides. The oxide 
activator bleaching activity of cyanopyridine has been proved by Rees W. M.21 , Oshida 
M.22 prepared cyanopyridine derivatives which inhibit cerebral edema and delayed 
neuron death. Hence, they are useful as cerebral edema inhibitors or cerebrovascular 
disorder remedies.  
          S. S. Verma et al.23 and M. D. Ankhiwala24 have synthesized 2-Amino-3-cyano- 
2,6-disubstituted pyrimidines and studied their biological activities. Several workers have 
prepared cyanopyridine derivatives and reported their cholinesterase inhibitors,25 
antihistaminic and antiallergic,26 adernergic,27 herbicidal,28 antiinflammatory29 and 
insecticidal30 activities. Some new 3-cyanopyridine derivatives synthesized by 
Hammama A. and coworkers31 showed anticancer and anti HIV-I activity. Abdallah N. et 
al.32 have synthesized and reported analgesic and antiinflammatory activity. Moreover 
Miertus et al.33 synthesized 2-Formylpyridinethiosemicarbazone as a carcinostatic agent. 
Atonso Adriano et al.34 have found cyanopyridines are Fernesyl protein transferase 
inhibitors. Hussain et al.35 have synthesized cyanopyridines as antimicrobial agent. Wu 
Wenxue et al.36 have synthesized cyanopyridines as histamine H3 antagonists. Saudi 
Manal N. S. et al.37 have found that cyanopyridines have fascialicidal property. Harada 
Hironori et al.38 have prepared cyanopyridines and screened for their large conductance 
calcium activated potassium channel opener activity. Dipeptidyl peptidase (DPP-IV) 
inhibition has the potential to become a valuable therapy for diabetes. Edwin B. Villhauer 
and co-worker39 have reported the first use of solid-phase synthesis in the discovery of a 
new DPP-IV inhibitor class and a solution-phase synthesis that is practical up to the 
multikilogram scale. One compound NVP-DPP728 (III) is profiled as a potent selective 
anhortacting. DPP-IV inhibitor that has excellent oral bioavailability and potent 
antihyperglycemic activity. 
 
                                                                                                                                                                            
 75
                                
N NH NH N
NC
CNO
(III)  
         
          Marco J. L. et al.40 have synthesized acetylcholinesterase inhibitors. Moustafa M. 
A. et al.41 have prepared antibacterial agents. Rosentreter Ulrich et al.42 have synthesized 
a new cyanopyridine as receptor agonists in the treatment of cancer disease , 
inflammation, neurodegenerative disease(IV). Gary T. Wang and co-worker43 have 
synthesized of o-Trifluoromethylbiphenyl substituted 2-Amino-nicotinonitriles as 
inhibitors of Farnesyltransferase(V). 
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          Thus, diverse biological activities have been encountered in compounds containing 
cyanopyridine ring system. Therefore it was considered wothwhile to synthesise 
cyanopyridine derivatives which have been described as under. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-6-   
ARYL-4-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-
3-CYANOPYRIDINES  
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SECTION-II: SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-
[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-MET- 
HOXY-3-CYANOPYRIDINES  
 
SECTION-III: SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-
[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-ETH- 
OXY-3-CYANOPYRIDINES  
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SECTION-I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-6-ARYL-4-[4’-
(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-3-CYANOPYRIDINES  
 
           Cyanopyridines play a vital role owing to their range of biological and 
physiological activites. In the light of these biological activities and variety of industrial 
applications, some new 2-Amino-6-aryl-4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
3-cyanopyridines derivatives of type (IV) have been prepared, by the cyclocondensation 
of 1-Aryl-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-propenones  type (I) with 
malononitrile in presence of ammonium acetate.. 
 
  
N
O
Cl
NH2
N
R
OCH3
Type (IV)      
O
O
CH3
Cl
OR
Type(I) R=Aryl
CH2(CN) 2
CH3COONH 4
 
          
            The structure elucidation of synthesized compounds has been done on the basis of 
Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry.Purity of all compounds have been checked by 
thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs. 
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IR SPECTRAL STUDIES OF 2-AMINO-6-(p-METHOXYPHENYL)-4-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-3-CYANOPYRIDINE 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2963.65 2975-2950 A 
-CH3 C-H str. (sym.) 2863.50 2880-2860 “ 
 C-H def. (asym.) 1456.40 1470-1435 “ 
Aromatic C-H str. 3030.50 3090-3030 “ 
 C=C str. 1514.62 1540-1480 “ 
 C-H i.p. (def.) 1172.17 1177-1027 “ 
 C-H o.o.p. (def.) 824.70 835-810 “ 
Nitrile C=N str. 2202.93 2350-2120 “ 
Pyridine C=C str. 1645.66 1650-1520 “ 
 C=N str. 1572.66 1580-1550 “ 
 N-H str. 3303.56 3440-3300 “ 
Methoxy C-O str. 1258.10 1260-1200 “ 
Halide C-Cl str. 771.53 800-600 “ 
Ether Ar-O-C str. 1219.08 1260-1200 “ 
 
O
Cl
O CH3
N
O
CH3
N
NH2
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NMR SPECTRAL STUDIES OF 2-AMINO-6-(p-METHOXYPHENYL)-4-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-3-CYANOPYRIDINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment of 
proton(s) 
1. 3.86 s 3 -- 7” 
2. 3.96 s 3 -- 7’ 
3. 5.18 s 2 -- 8’ 
4. 5.31 s 2 -- 7 
5. 6.95-7.98 m 12 -- 
5,2’,3’,6’,10’,1
1’,13’,14’,2”,3
”,5”,6”, 
Total No. of protons  22 
 
O
Cl
O
CH3
N
O
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N NH2
1
23
4
5
6
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8' 9' 10'
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MASS SPECTRAL STUDIES OF 2-AMINO-6-(p-METHOXYPHENYL)-4-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-3-CYANOPYRIDINE 
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MASS FRAGMENTATION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-6-ARYL-4-[4’-
(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-3-CYANOPYRIDINES 
  
(A)  Synthesis of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl- 
]-propenone 
         See [A], Part-I, Section-I (B). 
 
(B) Synthesis of 2-Amino-6-(p-methoxyphenyl)-4-[4’-(p-chlorobenzyloxy)-3’-metho-    
xyphenyl]-3-cyanopyridine 
          To a solution of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-
methoxyphenyl]-propenone (4.08g,0.01M), Malononitrile (0.75ml,0.012M) in methanol 
(40ml) add Ammonium acetate(6.16g,0.08M). The content was heated under reflux with 
stirring for 12 hr. The reaction mixture was converted to orange syrup type suspension, 
cooled to ambient temperature and solid precipitated out was filtered and residue was 
crystallized from ethanol. Yield 58%, m.p. 1800 C, (C27 H22ClN3O3; Required: C,68.71; 
H, 4.7; N, 8.90; Found: C, 68.69 ; H, 3.8; N,8.88 %. Similarly, other 2-Amino-6-aryl-4-
[4’-(p- chlorobenzyloxy)-3’-methoxyphenyl]-3-cyanopyridines were prepared. The 
physical data are recorded in Table No.4 
 
(C)   Biological evaluation of 2-Amino-6-aryl-4-[4’-(p-chlorobenzyloxy)-3’-methoxy-
phenyl]-3-cyanopyridines 
       Antimicrobial testing were carried out as described in [A], Part-I Section-1 (C). 
The zones of inhabition of test solutions are recorded in Graphical Chart No 04. 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Cyanopyridine derivatives tested 
compounds 4b,4d,4f and 4l showed greater degree of antibacterial activity against 
B.coccus. However, the compounds 4f,4h,4i and 4l showed greater degree of antibacterial 
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activity against B.subtilis. The compounds 4a,4c,4i  and 4j showed greater degree of 
antibacterial activity against E.coli. However, the compounds 4c,4e,4g and 4l showed 
greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Cyanopyridine derivatives tested 
compounds 4a,4d,4g  and 4h showed greater degree of antifungal activity against  
A.niger. 
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TABLE NO. 4: PHYSICAL CONSTANT OF 2-AMINO-6-ARYL-4-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENY- 
L]-3-CYANOPYRIDINES  
Comp.
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular 
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent
System
10 Calcd. 8
Found 
9 
4a -C6H5 C26H20ClN3O2 441.50 175 050 56 9.51 9.53 S1 
4b -4-OCH3-C6H4 C27H22ClN3O3 471.50 180 0.40 58 8.90 8.95 S1 
4c -4-Cl-C6H4 C26H19Cl2N3O2 476.00 163 070 74 8.82 8.80 S1 
4d -2,4-(Cl)2-C6H3 C26H18Cl3N3O2 510.50 180 0.36 66 8.23 8.20 S1 
4e -4-OH-C6H4 C26H20ClN3O3 457.50 190 0.42 52 9.18 9.30 S1 
4f -4-Br-C6H4 C26H19BrClN3O2 520.50 210 0.56 45 8.07 8.20 S1 
4g -4-NO2-C6H4 C26H19ClN4O4 486.50 220 0.58 35 11.51 11.60 S1 
4h -4-NH2-C6H4 C26H21ClN4O2 456.50 190 0.46 65 12.26 12.30 S1 
4i -2-OH-C6H4 C26H20ClN3O3 457.50 174 0.52 66 9.18 9.30 S1 
4j -4-CH3-C6H4 C27H22ClN3O2 455.50 150 0.42 68 9.22 9.35 S1 
4k -2,4-(OCH3)2-C6H3 C28H24ClN3O4 501.50 185 0.66 74 8.37 8.40 S1 
4l -4-(O-CH2-C6H5)-C6H4 C33H26ClN3O3 548.00 200 0.65 56 7.67 7.70 S1 
TLC Solvent system : S1 : Methanol:Dichloromethane(0.4:9.6); S2 : Ethyl acetate : Hexane(40:60) 
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GRAPHICAL CHART NO. 4:  ANTIMICROBIAL ACTIVITY OF 2-AMINO-6-ARYL-4-[4’-(p-CHLOROBENZYLOXY)-
3’-METHOXYPHENYL]-3-CYANOPYRIDINES 
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B.coccus 15 21 14 19 12 21 18 19 19 16 18 22 20 21 18 20 0
B.subtilis 19 14 19 14 18 20 15 22 23 17 12 21 24 24 17 18 0
E.coli 20 18 22 12 13 12 12 17 22 20 16 12 22 25 24 18 0
P.vulgaris 12 16 23 18 22 17 19 16 12 12 10 19 21 25 25 15 0
A.niger 18 12 18 21 17 16 22 20 17 18 18 18 0 0 0 0 24
4a 4b 4c 4d 4e 4f 4g 4h 4i 4j 4k 4l Ampicillin
Amoxi
cillin
Norflo
xacin
Benzyl 
Penicil
lin
Griseo
fulvin
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SECTION-II 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-[4’-(p-CHLOR-
OBENZYLOXY)-3’-METHOXYPHENYL]-2-METHOXY-3-CYANOPYRIDINES  
 
         6-Aryl-4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2-methoxy-3-cyanopyridines    
derivatives of type (V) have been prepared by the cyclocondensation of 1-Aryl-3-[4’-(p-
chlorobenzyloxy)-3’-methoxyphenyl]-propenones of  type (I) with malononitrile in 
presence of sodium methoxide. 
 
N
O
Cl
O
N
R
OCH3
CH3
Type (V)      
O
O
CH3
Cl
OR
Type(I) R=Aryl
CH2(CN)2
CH3ONa
 
           
          The structure elucidation of synthesized compounds has been done on the basis of 
Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry.Purity of all compounds have been checked by 
thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs.  
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IR SPECTRAL STUDIES OF 6-(p-METHOXYPHENYL)-4-[4’-(p-CHLOR-
OBENZYLOXY)-3’-METHOXYPHENYL]-2-METHOXY-3-CYANOPYRIDINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc)  
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2950.14 2975-2950 A 
-CH3 C-H def. (asym.) 1455.74 1470-1435 “ 
Aromatic C-H str. 3082.69 3090-3030 “ 
 C=C str. 1513.02 1540-1480 “ 
 C-H i.p. (def.) 1132.77 1177-1027 “ 
 C-H o.o.p. (def.) 823.84 835-810 “ 
Nitrile C=N str. 2218.10 2350-2120 “ 
Methoxy C-O str. 1259.68 1260-1200 “ 
Halide C-Cl str. 793.89 800-600 “ 
Ether Ar-O-C str. 1221.80 1260-1200 “ 
Pyridine C=C str. 1546.91 1650-1520 “ 
 C=N str. 1574.71 1580-1550 “ 
O
Cl
O
CH3
N
O
N
CH3
O
CH3
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NMR SPECTRAL STUDIES OF 6-(p-METHOXYPHENYL)-4-[4’-(p-CHLOR-
OBENZYLOXY)-3’-METHOXYPHENYL]-2-METHOXY-3-CYANOPYRIDINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
      No. Chemical Shift δ ppm Multiplicity 
No. of 
protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1. 3.88 s 3 -- 7” 
2. 3.97 s 3 -- 7’ 
3. 4.17 s 3 -- 7 
4. 5.18 s 2 -- 8’ 
 
5. 6.95-8.07 m 12 -- 
5,2’,3’,6’,10’,
11’,13’,14’, 
2”,3”,5”,6” 
Total No. of protons  23 
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MASS SPECTRAL STUDIES OF 6-(p-METHOXYPHENYL)-4-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-
2-METHOXY-3-CYANOPYRIDINE 
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MASS FRAGMENTATION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-[4’-(p-CHLOR-
OBENZYLOXY)-3’-METHOXYPHENYL]-2-METHOXY-3-CYANOPYRIDINES 
 
(A) Synthesis of 1-(4-methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
propenone 
       See [A],Part-I, Section-I (B). 
 
 
(B) Synthesis of 6-(p-Methoxyphenyl)-4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl- 
]-2-methoxy-3-cyanopyridine  
          To a solution of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-
methoxyphenyl]-propenone (4.08g,0.01M), malononitrile (0.75ml,0.012M) in methanol 
(40ml) add Sodium methoxide(1.08g,0.02M). The content was heated under reflux with 
stirring for 12 hr. The reaction mixture was converted to orange syrup type suspension, 
cooled to ambient temperature and solid precipitated out was filtered and  residue was 
crystallized from ethanol. Yield 85%, m.p. 1750 C, (C28 H23ClN2O4; Required: C,69.06; 
H, 4.76; N, 5.75; Found: C, 69.10 ; H, 4.82; N,5.81 %. S i m i l a r l y , o t h e r 6-Aryl-4-
[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2-methoxy-3-cyanopyridines were prepared. 
The physical data are recorded in Table No.5 
 
(C) Biological evaluation of 6-Aryl-4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2- 
      methoxy-3-cyanopyridines 
          Antimicrobial testing were carried out as described in [A], Part-I Section-1 (C).The 
zones of inhabition of test solution are recorded in Graphical Chart No 5. 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Methoxycyanopyridine derivatives tested 
compounds 5a,5c,5h and 5k showed greater degree of antibacterial activity against 
B.coccus. However, the compounds 5e,5f,5i and 5j showed greater degree of antibacterial 
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activity against B.subtilis. The compounds 5a,5d,5j  and 5l showed greater degree of 
antibacterial activity against E.coli. However, the compounds 5c,5f,5g and 5k showed 
greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Methoxycyanopyridine derivatives tested 
compounds 5a,5c,5e and 5g showed greater degree of antifungal activity against  A.niger. 
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TABLE NO.5:PHYSICAL CONSTANT OF 6-ARYL-4-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-
METHOXY-3-CYANOPYRIDINES 
Comp.
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular 
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent 
System 
10 Calcd. 8
Found
9 
5a -C6H5 C27H21ClN2O3 456.50 170 0.63 56 6.13 6.10 S1 
5b -4-OCH3-C6H4 C28H23ClN2O4 486.50 175 0.53 85 5.75 5.72 S1 
5c -4-Cl-C6H4 C27H20Cl2N2O3 491.00 156 0.54 74 5.70 5.75 S1 
5d -2,4-(Cl)2-C6H3 C27H19Cl3N2O3 525.50 185 0.42 65 5.33 5.26 S2 
5e -4-OH-C6H4 C27H21ClN2O4 472.50 200 0.36 52 5.92 5.93 S2 
5f -4-Br-C6H4 C27H20BrClN2O3 535.50 225 0.63 74 5.23 5.28 S1 
5g -4-NO2-C6H4 C27H20ClN3O5 501.50 232 0.65 56 8.37 8.40 S1 
5h -4-NH2-C6H4 C27H22ClN3O3 471.50 196 0.46 52 8.90 8.95 S2 
5i -2-OH-C6H4 C27H21ClN2O4 472.50 185 0.65 85 5.92 5.85 S1 
5j -4-CH3-C6H4 C28H23ClN2O3 470.50 156 0.35 74 5.95 5.92 S1 
5k -2,4-(OCH3)2-C6H3 C29H25ClN2O5 516.50 201 0.65 56 5.42 5.40 S1 
5l -4-(O-CH2-C6H5)-C6H4 C34H27ClN2O4 563.00 226 0.54 55 4.98 4.92 S2 
TLC Solvent system : S1 : Methanol:Dichloromethane(0.4:9.6); S2 : Ethyl acetate : Hexane(40:60) 
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GRAPHICAL CHART NO. 5 :  ANTIMICROBIAL ACTIVITY OF 6-ARYL-4-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-2-METHOXY-3-CYANOPYRIDINES 
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B.coccus 20 12 19 19 15 18 16 21 17 17 20 15 20 21 18 20 0
B.subtilis 21 18 14 19 22 21 17 19 23 22 17 21 24 24 17 18 0
E.coli 21 17 19 22 14 18 13 17 19 20 14 19 22 25 24 18 0
P.vulgaris 18 15 21 18 12 19 20 17 19 13 20 14 21 25 25 15 0
A.niger 20 18 21 18 20 18 21 20 19 18 17 20 0 0 0 0 24
5a 5b 5c 5d 5e 5f 5g 5h 5i 5j 5k 5l Ampicillin
Amoxi
cillin
Norflo
xacin
Benzyl 
Penicil
lin
Griseo
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SECTION-III 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-ETHOXY-3-CYANOPYRI-
DINES 
 
          6-Aryl-4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2-ethoxy-3-cyano pyridines  
derivatives of type (VI) have been prepared by the  cyclocondensation of 1-Aryl-3-[4’-(p-
chlorobenzyloxy)-3’-methoxyphenyl]-propenones of type (I) with malononitrile in 
presence of sodium ethoxide. 
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          The structure elucidation of synthesized compounds has been done on the basis of 
Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry. Purity of all compounds have been checked by 
thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs. 
 
 
 
 
 
 
 
                                                                                                                                                                            
 98
 
                                              
O
O
HO
Cl
R
O
O
O
Cl
O
R
R=Aryl
N
O
Cl
R
N
O
H5C2
O
H3C
Malononitrile
C2H5ONa
Type(VI)
REACTION SCHEME
 
 
                                                                                                                                                                            
 99
IR SPECTRAL STUDIES OF 6-(p-METHOXYPHENYL)-4-[4’-(p-CHLOROBEN-
ZYLOXY)-3’-METHOXYPHENYL]-2-ETHOXY-3-CYANOPYRIDINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2960.95 2975-2950 A 
-CH3 C-H str. (sym.) 2868.40 2880-2860 “ 
 C-H def. (asym.) 1455.75 1470-1435 “ 
Aromatic C-H str. 3084.85 3090-3030 “ 
 C=C str. 1492.05 1540-1480 “ 
 C-H i.p. (def.) 1138.85 1177-1027 “ 
 C-H o.o.p. (def.) 809.93 835-810 “ 
Nitrile C=N str. 2219.58 2350-2120 “ 
Methoxy C-O str. 1258.47 1260-1200 “ 
Halide C-Cl str. 773.27 800-600 “ 
Ether Ar-O-C str. 1242.03 1260-1200 “ 
Pyridine C=C str. 1574.92 1650-1520 “ 
 C=N str. 1545.14 1580-1550 “ 
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NMR SPECTRAL STUDIES OF 6-(p-METHOXYPHENYL)-4-[4’-(p-CHLOROB-
ENZYLOXY)-3’-METHOXYPHENYL]-2-ETHOXY-3-CYANOPYRIDINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
  No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1. 1.51 t 3 7.06 8 
2. 3.87 s 3 -- 7” 
3. 3.97 s 3 -- 7’ 
4. 4.64 q 2 7.08 7 
5. 5.18 s 2 -- 8’ 
 
6. 6.95-8.05 m 12 -- 
5,2’,3’,6’,10’,
11’,13’,14’,2”
,3”,5”,6” 
Total No. of protons  25 
O
Cl
O
CH3
N
O
N
O
CH3
H3C
1
23
4
5
6
7
1'
2'
3'
4'
5'
6'
8' 9' 10'
11'
12'
13'
14'
1" 2"
3"
4"
5"
6"
7"
8
7'
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MASS SPECTRAL STUDIES OF 6-(p-METHOXYPHENYL)-4-[4’-(p-CHLOROB-ENZYLOXY)-3’-METHOXYPHENYL]-
2-ETHOXY-3-CYANOPYRIDINE 
 
 
 
O
Cl
O
CH3
N
O
N
O
CH3
H3C
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-ETHOXY-3-CYANOPYRI-
DINES 
 
(A) Synthesis of 1-(4-methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-   
propenone 
 
      See [A],Part-I, Section-I (B). 
 
(B) Synthesis of 6-(4-Methoxyphenyl)-4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
2-ethoxy-3-cyanopyridine  
          To a solution of 1-(4-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-
methoxyphenyl]-propenone (4.08g, 0.01M), malononitrile (0.75ml, 0.012M) in methanol 
(40ml) add Sodium ethoxide (1.36g, 0.02M). The content was heated under reflux with 
stirring for 12 hr. The reaction mixture was converted to orange syrup type suspension, 
cooled to ambient temperature and solid precipitated out was filtered and residue was 
crystallized from ethanol. Yield 55%, m.p. 1500 C, (C29 H25ClN2O4; Required: C, 69.53; 
H, 5.03; N, 5.59; Found: C, 69.59; H, 4.92; N, 5.68 %. S i m i l a r l y, o t h e r 6-Aryl-4-
[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2-ethoxy-3-cyanopyridines were prepared. 
The physical data are recorded in Table No.6 
 
(C) Biological evaluation of 6-Aryl-4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2-
ethoxy-3-cyanopyridines 
         Antimicrobial testing were carried out as described in [A], Part-I, Section-1 (C).The 
zones of inhabition of test solution are recorded in Graphical Chart No 6. 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Ethoxycyanopyridine derivatives tested 
compounds 6a,6d,6i and 6j showed greater degree of antibacterial activity against 
B.coccus. However, the compounds 6a,6d,6e and 6i showed greater degree of 
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antibacterial activity against B.subtilis. The compounds 6c,6d,6f  and 6i showed greater 
degree of antibacterial activity against E.coli. However, the compounds 6a,6b,6e and 6g 
showed greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Ethoxycyanopyridine derivatives tested 
compounds 6b,6f,6g and 6h showed greater degree of antifungal activity against  A.niger. 
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TABLE NO.6: PHYSICAL CONSTANT OF 6-ARYL-4-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-
ETHOXY-3-CYANOPYRIDINES 
Comp. 
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular 
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent
System
10 Calcd. 8
Found
9 
6a -C6H5 C28H23ClN2O3 470.50 163 0.52 63 5.95 5.90 S1 
6b -4-OCH3-C6H4 C29H25ClN2O4 500.50 150 0.43 55 5.59 5.65 S1 
6c -4-Cl-C6H4 C28H22Cl2N2O3 505.00 174 0.55 52 5.54 5.60 S1 
6d -2,4-(Cl)2-C6H3 C28H21Cl3N2O3 539.50 192 0.46 45 5.19 5.25 S1 
6e -4-OH-C6H4 C28H23ClN2O4 486.50 210 0.39 75 5.75 5.80 S1 
6f -4-Br-C6H4 C28H22BrClN2O3 549.50 230 0.62 62 5.09 5.10 S1 
6g -4-NO2-C6H4 C28H22ClN3O5 515.50 196 0.55 55 8.14 8.20 S1 
6h -4-NH2-C6H4 C28H24ClN3O3 485.50 200 0.49 42 8.65 8.60 S1 
6i -2-OH-C6H4 C28H23ClN2O4 486.50 189 0.52 35 5.75 5.72 S1 
6j -4-CH3-C6H4 C29H25ClN2O3 484.50 160 0.35 71 5.78 5.73 S1 
6k -2,4-(OCH3)2-C6H3 C30H27ClN2O5 530.50 220 0.63 65 5.28 5.21 S1 
6l -4-(O-CH2-C6H5)-C6H4 C35H29ClN2O4 577.00 230 0.52 55 4.85 4.82 S1 
TLC Solvent system : S1 : Methanol:Dichloromethane(0.4:9.6); S2 : Ethyl acetate : Hexane 
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GRAPHICAL CHART NO. 6: ANTIMICROBIAL ACTIVITY OF  6-ARYL-4-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-2-ETHOXY-3-CYANOPYRIDINES 
0
5
10
15
20
25
30
Z
O
N
E
 
O
F
 
I
N
H
I
B
I
T
I
O
N
 
I
N
 
m
m
B.coccus 20 17 15 19 12 18 17 12 19 20 19 20 20 21 18 20 0
B.subtilis 19 12 18 20 23 17 15 21 22 10 16 18 24 24 17 18 0
E.coli 12 19 21 20 14 22 13 17 20 10 18 20 22 25 24 18 0
P.vulgaris 20 18 14 17 20 18 20 17 13 18 17 12 21 25 25 15 0
A.niger 18 20 17 18 12 19 22 20 17 18 18 18 0 0 0 0 24
6a 6b 6c 6d 6e 6f 6g 6h 6i 6j 6k 6l Ampicillin
Amoxi
cillin
Norflo
xacin
Benzyl 
Penicil
lin
Griseo
fulvin
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PART-III : STUDIES ON PYRIMIDINES 
 
INTRODUCTION 
 
          Pyrimidine is the most important member of all the diazines as this ring system 
occurs widely in living organisms. Pyrimidine and its derivatives have gained 
prominence bacause of their potential pharmaceutical values. Many pyrimidine 
derivatives play vital role in many physiological actions. They are among those 
molecules that make life possible as being some of the building blocks of DNA and 
RNA. 
                                                        
NN
(I)  
     
          Pyrimidine is considered to be a resonance hybrid of the charged and uncharged 
cannonical structures; its resonance energy has been found to be less than benzene or 
pyridine. The naturally occuring pyrimidine derivative was first isolated by Gabrial and 
Colman in 1870 and its structure was confirmed in 1953 as 5-β-D-glucopyranoside of 
divicine. 
 
SYNTHETIC ASPECT 
 
          A very important general method for preparing pyrimidines is the condensation 
between a three carbon compounds of the type YCH2Z, where Y and Z = COR, CO2R, 
CN, and compounds having the amidine structure R(C=NH)NH2, where R = R (an 
amidine), OH (urea), SH or SR (thiourea or its s-derivative), NH2 (guanidine); the 
condensation is carried out in the presence of sodium hydroxide or sodium ethoxide. This 
general reaction may be illustrate by the condensation of acetamidine with 
ethylacetoacetate to form 4-Hydroxy-2, 6-dimethylpyrimidine. 
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NH2 NH
NH2
+ H5C2O
CH2
CH3O
N
NH
NH2 CH3
O
N
N
NH2 CH3
OH
 
 
          Pyrimidines can also be prepared by cycloaddition reaction of 1,3,5- 
triazines,which act as electron deficient dienes.  
 
                              
N
N
N CH3 N(C2H5)2 N
N
CH3
(H5C2)2N
 
 
 
          There are many other methods of pyrimidine ring synthesis which are of more 
limited scope. The reaction of 1,3-Dicarbonyl compound or an equivalent reagent with 
formamide provides a route of several pyrimidine which are unsubstituted at the 2-
position.  
 
PhNMeHC CH CHO
HCONH2
2000 C
HOCHNHC CH CHO
HCONH2
N
N
 
 
Some other examples of pyrimidine synthesis are as under. 
 
CH3 C N3
KOMe
1400C
NH
NCH3 CH3
N
N
N CH3
NH2
CH3
(PhCO)2CH2+
CHO
NH4OAc
Me2SO, 80
0C
N
NPh Ph
Ph
N
NPh Ph
Ph
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REACTION MECHANISM 
 
The reaction mechanism for the formation of pyrimidine derivatives described as under. 
 
R R1
O
+
R2
NH2 NH2
Alkali
NH
O
R1R
R2
NH2
NHNH
R1R
OH
R2
NHN
R1R
R2
HO-
-H+,-H- NN
R1R
R2
Where, R2 = SH, NH2
 
THERAPEUTIC IMPORTANCE 
          It is revealed from the literature survey that pyrimidine derivatives have been 
found possessing biological activities reported as under. 
1. Fungicidal1 
 
2. Insecticidal2 
 
3. Anticonvulsant3 
 
4. Antitubercular4 
 
5. Tranquilizing5 
 
6. Antidiabetic6 
 
7. Antihypertensive7 
 
8. Analgesic8 
 
9. Antibacterial9 
 
10. Diuretic10 
          S. S. Sangopure and A. M. Mulogi 11 have tested the antimicrobial activity of 
Benzofuro[3,2-d]pyrimidine derivatives (II). El Sayed12 and A. M. Badaway have 
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synthesized alkylated substituted mercapto pyrimidine derivatives (III) and studied their 
anticancer and antineoplastic activity. H. Y. Moustafa13 have reported some pyrimidine 
derivatives and studied their biological activities.  
                       
O
N
H
S
NH2
(II)
N
N
Cl
CH3H3CS
(III)
 
 
          The pyrimidines uracil (IVa), thyamine (IVb) and cytosine (V) occur very widely 
in nature since they are components of nucleic acids, in the form of N-substituted sugar 
derivatives. Several analogues have been used as compounds that interfere with the 
synthesis and functioning of nucleic acids: examples are fluorouracil (IVc) and the anti-
AIDS drug Zidovudine (AZT) (VI). Some diaminopyrimidines, including pyrimethamine 
(VII) and trimethoprim (VIII) are antimalarial agents; trimethoprim is also an effective 
antibacterial agent when used in combination with a sulphonamide. Minoxidil (IX) is a 
vasodilator which has been used in the treatment of hypertension. Vitamine B1(X) is also 
a pyrimidine.  
NH
N
H
O
O
R
(IV)
N
N
H
NH2
O
(V)
NH
CH3
O
O
O
OH
N3
(VI)
N
N
Cl
NH2
NH2H5C2
(VII)
N
N
NH2 NH2
O
O
CH3
CH3
O
CH3
(VIII)
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N
N
N+
NH2
O
NH2
(IX)
S
N+ N
N+
CH3
HOH2CH2C
H
CH3
NH2
(X)  
 
          Patil L. R. et al.14 have synthesized some new pyrimidines bearing paracetamol and 
imidazolyl moieties. B.J.Ghiya et al.15 synthesized some Mercaptopyrimidine derivatives 
(XI) and screened for their anticancer, antitubercular and anti HIV activities. Kaplina N. 
V. and co-workers16 show herpes inhibiting activity of some mercaptopyrimidine 
derivatives.  
   
NH
NN
R1
R2
CH3 NH2
R3
(XII)
NN
R2
R1R3
R4
SH
R5
(XI)  
 
          Moreover, Chaudhari Bipinchandra et al.17 prepared (XII) as N-type calcium 
channel antagonists for the treatment of pain. Devi E. Sree and co-workers18 have 
prepared pyrimidine derivatives and tested for antimicrobial activity. Kovalenko A. L.19 
synthesized and reported antifungal activity of pyrimidine derivatives. Shiv P. Singh and 
co-workers20 synthesized 4-(4-Pyrazolyl)-2-aminopyrimidines  and tested them for their 
antimicrobial activity. Some Pyrazolothienopyrimidine derivatives exhibit antiulcer 
activity. Skolova A. S. and co-workers21 have synthesized 5-Amino-6-mercapto 
pyrimidine possessing antitumor and cytostatic activity. Hozein Zeinab et al.22 and 
Khalafallah Ali Kamel23 have prepared mercapto derivatives and screened for their 
antibacterial and antifungal activity.  
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          H.S.Joshi et al.24 has sythesized some new pyrimidines as antitubercular and 
antimicrobial activity (XIII). 
 
                                                        
NH
N SHR
Br
(XIII)  
 
           Marie Gompel and co-worker25 have showed that meridianins inhibit various 
protein kinases such as cyclin-dependent kinases, glycogen synthases kinases-3, cyclic 
nucleotide-dependent kinases and casein kinases (XIV). Alistair H et al26 have 
synthesized a novel series of aminopyrimidine IKK2 inhibitors which show excellent in 
vitro inhibition of this enzyme and good selectivity over the IKK1 isoform. The relative 
potency and selectivity of these compounds has been rationalized using QSAR and 
structure-based modelling (XV). 
   
N
H
N
N
R
R
R
R
NH2
(XIV)
Meridianin A : OH     H     H     H
Meridianin B : OH     H     Br     H
Meridianin C :   H     Br     H     H
Meridianin D :   H     H     Br     H
Meridianin E : OH     H     H     Br
Meridianin F :   H     Br     Br     H
Meridianin G :   H     H     H     H
Where,
N
N
H
S
N
N NH
OO
R
(XV)  
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           Aleem Gangjee et al.27 have designed and synthesized some novel analogues of N-
{4-[2-(2-Amino-4-ethylpyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid as 
potential inhibitors of Thymidylate synthesis (TS), Dihydrofolate reductase (DHFR) and 
as antitumor agents (XVI). Antonello Mai et al.28 have described 2-Alkylamino-6-[1-(2,6 
difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones, (F2-NH-DABOs)4,5 
belonging to the Dihydro-alkoxy-benzyl-oxopyrimidine (DABO) family and bearing 
different alkyl and arylamino side chains at the C2 -position of the pyrimidine ring were 
active against wild type (wt) human immunodeficiency virus (HIV-1) and some relevant 
HIV-1 mutants(XVII). 
         
N
N
NH
NH
COOH
NH2 CH3
R
O COOH
(XVI)
N
NH
O
R
NH
X
R1
FF
(XVII)
R = R 1  = H, X = Aryl, Alkyl, Arylalkyl
Where,
 
 
 
          Viney Lather and co-worker29 have  proposed to predict the anti-HIV activity of 
Dihydro-(alkylthio)-(naphthylmethyl)-oxopyrimidines. These models are capable of 
providing lead structures for development of potent but safe anti-HIV agents(XVIII). 
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N
NH
O
R1
RS
X
(XVIII)  
 
          Gompel M et al.30 have prepared new family of protein kinase inhibitors isolated 
from the ascidian aplidium meridianum. Mai A. et al.31 have synthesized 5-Alkyl-2-
alkylamino-6(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of 
potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the 
DABO family. Yamamoto32 have reported some oxopyrimidines searching for the novel 
antagonist or agonist of barbiturates to the sleep mechanism based on the uridine 
receptor. Huang Y.L. et al.33 have synthesized non-classical antifolates, 5-(N 
Phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines and 2,4-Diamino-6(5H) 
oxopyrimidines as antitumor activity.  
          Shimizu T., Kimura T. et al.34 have described N3-substituted uridine and related 
pyrimidine nucleosides as antinociceptive effects in mice. Sanmartin C. et al.35 have 
prepared new symmetrical derivatives as cytotoxic agents and apoptosis inducers. 
Agarwal A. et al.36 have synthesized 2,4,6-Trisubstituted pyrimidine derivatives as 
pregnancy interceptive agents.  
          Whittingham J. L. et al.37 have described pyrimidine ring as a platform for 
antimalarial drug for the selectivity of a class of nucleoside inhibitors. Han G. Z. et al.38 
documented the pyrimidine derivatives as anticancer actions of 2-Methoxyestradiol and 
microtubule-disrupting agents in human breast cancer. Tack D. K. et al.39 reported 
anthracycline vs nonanthracycline therapy for breast cancer. Cano-Soldado P. et al.40 
have described pyrimidine nucleous as interaction of nucleoside inhibitors of HIV-1 
reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Gompel 
M. et al.41 have isolated a new family of protein kinase inhibitors from the ascidian 
aplidium meridianum. Junmei Wang et al.42 have prepared and described for HIV-1 
Reverse Transcriptase (XIX). 
 
                                                                                                                                                                            
 119
 
                                                  
NHNH
Cl
O
F F
F
(XIX)  
 
          Looking to the diversified activities exhibited and in continuation of our work 
on the synthesis of biologically active heterocycles, the synthesis and biological 
screening of pyrimidine derivatives have been described as under. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-[4’-
(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1H-PYRIMI- 
DINE-2-ONES  
 
SECTION-II: SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-
[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1H-PYRI- 
MIDINE-2-THIONES  
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SECTION–I  
 SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1H-PYRIMIDINE-2-ONES  
 
                In the past years considerable evidence has been accumulated to demonstrate 
the efficiency of pyrimidinones. 4-Aryl-6-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]- 
1H-pyrimidine-2-ones of type (VII) have been prepared by the condensation of 1-Aryl-3-
[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-propenone  of type-(I) with urea in presence 
of catalytic amount of  NaOH as shown under.  
 
 
                  
O
O
CH3
Cl
O
R
O
Cl
R N
NH
O
O
CH3
NH2 NH2
O
Type(I) Type(VII) R=Aryl
 
 
 
          The structure elucidation of synthesized compounds has been done on the basis of 
Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry. Purity of all compounds have been checked by 
thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
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bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs.  
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IR SPECTRAL STUDIES OF 4-(p-METHOXYPHENYL)-6-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1H-PYRIMIDINE-2-ONE  
 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2954.54 2975-2950 A 
-CH3 C-H str. (sym.) 2868.95 2880-2860 “ 
 C-H def. (asym.) 1464.79 1470-1435 “ 
Aromatic C-H str. 3055.65 3090-3030 “ 
 C=C str. 1505.56 1540-1480 “ 
 C-H i.p. (def.) 1125.17 1125-1090 “ 
 C-H o.o.p. (def.) 810.60 835-810 “ 
Methoxy C-O str. 1258.80 1260-1200 “ 
Halide C-Cl str. 759.16 800-600 “ 
Ether Ar-O-C str. 1207.06 1260-1200 “ 
Pyrimidine C=C str. 1641.54 1650-1520 “ 
 C=N str. 1573.35 1612-1593 “ 
 N-H str. 3431.31 3440-3300 “ 
oxopyri. C=O str. 1663.26 1672-1652 “ 
O
Cl
O
CH3
NNH
O
O
CH3
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NMR SPECTRAL STUDIES OF 4-(p-METHOXYPHENYL)-6-[4’-(p-CHLOROB-
ENZYLOXY)-3’-METHOXYPHENYL]-1H-PYRIMIDINE-2-ONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1. 3.88 s 3 -- 7” 
2. 3.94 s 3 -- 7’ 
3. 5.23 s 2 -- 8’ 
 
      4. 7.08-8.20 m 12 -- 
5,2’,3’,6’,10’,
11’,13’,14’,2”
,3”,5”,6” 
Total No. of protons  20 
O
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MASS SPECTRAL STUDIES OF OF 4-(4-METHOXYPHENYL)-6-[4’-(p-CHLOROB-ENZYLOXY)-3’-METHOXYPHE- 
NYL]-1H-PYRIMIDINE-2-ONE 
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MASS FRAGMENTATION 
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  EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-6-[4’-(p-CHLOROB-
ENZYLOXY)-3’-METHOXYPHENYL]-1H-PYRIMIDINE-2-ONES 
 
  (A) Synthesis of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-    
propenone   
      See  [A],Part-I, Section-I (B). 
 
(B) Synthesis of 4-(p-Methoxyphenyl)-6-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
1H-pyrimidine-2-one 
           A solution of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’ 
methoxyphenyl]-propenone (4.08g, 0.01M) and urea (1.2g, 0.02M) in ethanol (40ml) was 
refluxed in presence of KOH (catalytic amount) for 10 hr. The separated solid was 
filtered out and crystallized from ethanol. Yield 45%, m.p.2150C. (C25 H21ClN2O4; 
Required: C, 66.89; H, 4.72; N, 6.24; Found: C, 66.70 ; H, 4.82; N,6.21 %. Similarly, 
other 4-Aryl-6-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-1H-pyrimidine-2-ones  were 
prepared. The physical data are recorded in Table No. 7. 
 
(C) Biological evaluation of 4-Aryl-6-[4’-(p chlorobenzyloxy)-3’-methoxy- phenyl]- 
1H-pyrimidine-2-ones 
          Antimicrobial testing were carried out as described in [A], Part-I, Section-I(C). The 
zones of inhibition of test solutions are reported in Graphical Chart No. 7. 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Oxopyrimidine derivatives tested 
compounds 7a,7e,7f and 7g showed greater degree of antibacterial activity against 
B.coccus. However, the compounds 7b,7c,7f and 7g showed greater degree of 
antibacterial activity against B.subtilis. The compounds 7d,7e,7i  and 7j showed greater 
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degree of antibacterial activity against E.coli. However, the compounds 7b,7d,7k and 7l 
showed greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Oxopyrimidine derivatives tested 
compounds 7b,7e,7f and 7i showed greater degree of antifungal activity against  A.niger. 
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TABLE NO.7: PHYSICAL CONSTANT OF 4-ARYL-6-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1H-
PYRIMIDINE-2-ONES  
Comp.
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent
System
10 Calcd. 8
Found 
9
7a -C6H5 C24H19ClN2O3 418.50 210 0.53 56 6.69 6.60 S1 
7b -4-OCH3-C6H4 C25H21ClN2O4 448.50 215 0.55 45 6.24 6.20 S1 
7c -4-Cl-C6H4 C24H18Cl2N2O3 453.00 230 0.41 55 6.18 6.23 S2 
7d -2,4-(Cl)2-C6H3 C24H17Cl3N2O3 487.50 203 0.62 52 5.74 5.78 S1 
7e -4-OH-C6H4 C24H19ClN2O4 434.50 230 0.44 43 6.44 6.33 S2 
7f -4-Br-C6H4 C24H18BrClN2O3 497.50 222 0.63 32 5.63 5.62 S1 
7g -4-NO2-C6H4 C24H18ClN3O5 463.50 212 0.58 41 9.06 9.10 S2 
7h -4-NH2-C6H4 C24H20ClN3O3 433.50 214 0.53 35 9.68 9.60 S2 
7i -2-OH-C6H4 C24H19ClN2O4 434.50 196 0.56 52 6.44 6.42 S1 
7j -4-CH3-C6H4 C25H21ClN2O3 432.50 198 0.41 42 6.47 6.52 S2 
7k -2,4-(OCH3)2-C6H3 C26H23ClN2O5 478.50 223 0.56 44 5.85 5.83 S1 
7l -4-(O-CH2-C6H5)-C6H4 C31H25ClN2O4 524.50 241 0.45 47 5.34 5.50 S2 
TLC Solvent system : S1 : Methanol:Dichloromethane(0.4:9.6); S2 : Ethyl acetate : Hexane(40:60) 
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GRAPHICAL CHART NO. 7 : ANTIMICROBIAL ACTIVITY OF 4-ARYL-6-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-1H-PYRIMIDINE-2-ONES  
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B.coccus 18 17 15 12 18 20 19 18 12 17 17 18 20 21 18 20 0
B.subtilis 17 21 20 18 17 22 23 20 17 18 12 18 24 24 17 18 0
E.coli 14 18 19 20 22 18 17 19 20 21 17 15 22 25 24 18 0
P.vulgaris 15 22 18 21 20 18 17 16 17 12 20 22 21 25 25 15 0
A.niger 18 22 17 19 23 21 18 17 20 17 19 18 0 0 0 0 24
7a 7b 7c 7d 7e 7f 7g 7h 7i 7j 7k 7l Ampicillin
Amoxi
cillin
Norflo
xacin
Benzyl 
Penicil
lin
Griseo
fulvin
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SECTION – II 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-[4’-(p-CHLOR- 
OBENZYLOXY)-3’-METHOXYPHENYL]-1H-PYRIMIDINE-2-THIONES 
 
           Thiopyrimidines represent one of the most active classes of compounds possessing 
a wide spectrum of biological activities, such as significant in vitro activity against 
unrelated DNA and RNA viruses including Polio Viruses, diuretic, antitubercular 
spermicidal etc. These valid observation led us to synthesize 4-Aryl-6-[4’-(p 
chlorobenzyloxy)-3’-methoxyphenyl]-1H-pyrimidin-2-thiones of type (VIII) by 
cyclocondensation of 1-Aryl-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-propenones 
of type-(I) and thiourea in presence of NaOH as catalyst.  
                                  
O
O
CH3
Cl
O
R
O
Cl
R N
NH
S
O
CH3
NH2 NH2
S
Type(I)
Type(VIII) R=Aryl
 
 
          The structure elucidation of synthesized compounds has been done on the basis of 
Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry. Purity of all compounds have been checked by 
thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
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bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs.  
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IR SPECTRAL STUDIES OF 4-(p-METHOXYPHENYL)-6-[4’-(p-CHLOROBEN- 
ZYLOXY)-3’-METHOXYPHENYL]-1H-PYRIMIDINE-2-THIONE 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2974.44 2975-2950 A 
-CH3 C-H str. (sym.) 2862.61 2880-2860 “ 
 C-H def. (asym.) 1463.71 1470-1435 “ 
Aromatic C-H str. 3030.00 3090-3030 “ 
 C=C str. 1512.83 1540-1480 “ 
 C-H i.p. (def.) 1088.79 1125-1090 “ 
 C-H o.o.p. (def.) 813.28 835-810 “ 
Methoxy C-O str. 1253.62 1260-1200 “ 
Halide C-Cl str. 798.53 800-600 “ 
Ether Ar-O-C str. 1233.28 1260-1200 “ 
Pyrimidine C=C str. 1543.36 1650-1520 “ 
 C=N str. 1576.33 1580-1550 “ 
 N-H str. 3377.03 3440-3300 “ 
Thiopyri. C=S str. 1179.71 1300-1100 “ 
 
O
Cl
O
CH3
NNH
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CH3
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NMR SPECTRAL STUDIES OF 4-(p-METHOXYPHENYL)-6-[4’-(p-CHLOROB- 
ENZYLOXY)-3’-METHOXYPHENYL]-1H-PYRIMIDINE-2-THIONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1. 3.82 s 3 -- 7” 
2. 3.88 s 3 -- 7’ 
3. 5.1 s 2 -- 8’ 
 
4. 6.80-7.37 m 12 -- 
10’,14’ 
11’,13’,3”,5” 
5,2’,3’,6’,2”,6
” 
5. 7.68 b 1 -- 3 
Total No. of protons  21 
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MASS SPECTRAL STUDIES OF 4-(p-METHOXYPHENYL)-6-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-
1H-PYRIMIDINE-2-THIONE 
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MASS FRAGMENTATION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-[4’-(p-CHLOR- 
OBENZYLOXY)-3’-METHOXYPHENYL]-1H-PYRIMIDINE-2-THIONES 
 
(A) Synthesis of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]- 
propenone   
      See [A], Part-I, Section-I (B). 
 
(B) Synthesis of 4-(p-Methoxyphenyl)-6-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]- 
-1H-pyrimidine-2-thione 
          A mixture of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’- 
methoxyphenyl]-propenone (4.08g, 0.01M) and thiourea (1.52g, 0.02M) in ethanol(40ml) 
was refluxed on a oil-bath in presence of alcoholic KOH(catalytic amount) for 10 hr. The 
separated solid was filtered out and crystallized from ethanol. Yield 56 %, m.p. 1900 C 
(C25 H21ClN2O3S; Required: C, 64.58; H, 4.55; N, 6.02; Found: C, 64.40; H, 4.66; N, 
6.11 %. Similarly, other 4-Aryl-6-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-1H-
pyrimidine-2-thiones were prepared. The physical data are recorded in Table No. 8. 
 
(C) Biological evaluation of 4-Aryl-6-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
1H-pyrimidine-2-thiones 
          Antimicrobial testing was carried out as described in [A],Part-I, Section-I(C). The 
zones of inhibition of test solution are reported in Graphical Chart No. 8. 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Thiopyrimidine derivatives tested 
compounds 8a,8b,8e and 8j showed greater degree of antibacterial activity against 
B.coccus. However, the compounds 8a,8b,8c and 8l showed greater degree of 
antibacterial activity against B.subtilis. The compounds 8a,8g,8i  and 8l showed greater 
degree of antibacterial activity against E.coli. However, the compounds 8b,8d,8e and 8l 
showed greater degree of antibacterial activity against P.vulgaris. 
                                                                                                                                                                            
 139
 
Antifungal activity 
           The screening data indicated that among Thiopyrimidine derivatives tested 
compounds 8e,8j,8k and 8l showed greater degree of antifungal activity against  A.niger. 
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TABLE No. 08 : PHYSICAL CONSTANTS OF 4-ARYL-6-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-1H-
PYRI- MIDINE-2-THIONES 
Comp.
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent 
System
10 Calcd. 8
Found 
9 
8a -C6H5 C24H19ClN2O2S 434.50 185 0.46 70 6.44 6.40 S2 
8b -4-OCH3-C6H4 C25H21ClN2O3S 464.50 190 0.38 56 6.02 6.10 S2 
8c -4-Cl-C6H4 C24H18Cl2N2O2S 469.00 210 0.48 82 5.97 5.92 S2 
8d -2,4-(Cl)2-C6H3 C24H17Cl3N2O2S 503.50 202 0.56 47 5.56 5.52 S1 
8e -4-OH-C6H4 C24H19ClN2O3S 450.50 220 0.56 55 6.21 6.16 S1 
8f -4-Br-C6H4 C24H18BrClN2O2S 513.50 210 0.57 56 5.45 5.49 S1 
8g -4-NO2-C6H4 C24H18ClN3O4S 479.50 208 0.48 71 8.76 8.79 S2 
8h -4-NH2-C6H4 C24H20ClN3O2S 449.50 203 0.44 44 9.34 9.31 S2 
8i -2-OH-C6H4 C24H19ClN2O3S 450.50 190 0.48 55 6.21 6.23 S1 
8j -4-CH3-C6H4 C25H21ClN2O2S 448.50 180 0.50 60 6.24 6.28 S1 
8k -2,4-(OCH3)2-C6H3 C26H23ClN2O4S 494.50 220 0.47 62 5.66 5.69 S1 
8l -4-(O-CH2-C6H5)-C6H4 C31H25ClN2O3S 571.00 186 0.40 63 5.18 5.25 S2 
   TLC Solvent system : S1 : Methanol:Dichloromethane(0.4:9.6); S2 : Ethyl acetate : Hexane(40:60) 
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MASS FRAGMENTATION 
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GRAPHICAL CHART NO. 8: ANTIMICROBIAL ACTIVITY OF 4-ARYL-6-[4’-(p-CHLOROBENZYLOXY)-3’-METHO- 
XYPHENYL]-1H-PYRIMIDINE-2-THIONES 
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B.coccus 20 19 11 15 19 15 14 11 12 20 14 11 20 21 18 20 0
B.subtilis 20 21 19 15 17 12 16 14 18 12 12 20 24 24 17 18 0
E.coli 20 18 14 16 12 18 20 10 22 21 18 19 22 25 24 18 0
P.vulgaris 15 22 18 20 21 18 11 19 12 12 17 20 21 25 25 15 0
A.niger 18 15 14 20 22 17 11 10 19 22 20 20 0 0 0 0 24
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PART-IV : STUDIES ON INDAZOLES 
 
INTRODUCTION 
 
          Heterocyclic compounds bearing 1,2-diazole ring system i.e. pyrazole ring system, 
attached to benzene ring system are known as benzopyrazole or indazole  
 
(I). Indazole was first described by Buchner in 1869. 
  
                                                          
N
N
H
(I)  
 
          Although the chemistry of indazoles has been extensively studied, they have not 
been found in natural products and are at the present time of little commercial 
use.Indazole can be considered as either azoindazoles or azoisoindazoles.The compounds 
of medicinal interest in this group so far have been non steroidal antiinflammatory agents 
or analgesic. 
 
SYNTHETIC ASPECT 
 
          Several methods have been reported in the literature 1,2,3,4,5,6 for the preparation of 
indazoles. 
1. Cyclocondensation of activated acetylenes with hydrazine afforded indazole 
derivatives. 
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2. B. V. Badami et al.7 have synthesized indazoles from chalcone derivatives via 
cyclohexenone derivatives as follow. 
 
R1
O
R
K2CO3
Ethylacetoacetate
(Dry Acetone) R O
COOEt
R1
NH2NH2.H2O
NH
NR
R1 O
 
3. A facile synthesis of substituted indazoles from 2-Acyl mesylates and hydrazines has 
been described by Caron S. et al.8 
 
THERAPEUTIC EVALUATION 
 
          It is revealed from the literature survey that indazole derivatives are better 
therapeutic agents and they have been found possessing various biological activities 
reported as under. 
1. Antiallergic9 
 
2. Antiviral10 
 
3. Antipsychotics11 
 
4. Herbicidal12 
 
5. Fungicidal13 
 
6. Antibacterial14 
 
7. Cardiovascular15 
 
8. Antidepressant16 
 
9. Antineoplastic17 
 
10. Antitumor18,19 
 
          Balakrishna and co-workers20 have synthesized indazole derivatives and evaluated 
them as antiinflammatory and analgesic activity. Malmstroem J.et al.21 have prepared 
indazoles (II) as inhibitors of Jun N-terminal kinases (JNK). Aminoindazoles (III) are 
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useful in the treatment of central and peripheral nervous system diseases have been 
synthesized.22 
 
 
                  
N
H
N
NH
Cl
Ph
(II)
N
N
H
NH
O
COOH
Cl
(III)  
 
          Butera J. A. et al.23 have prepared some indazole derivatives which showed 
antihypertensive, muscle relaxant and potassium activator activity. Several workers have 
patented indazole derivatives useful as hypolipidemic agent24, 5-HT3 antagonist25 
enzyme inhibitor26 etc. Some indazole derivatives investigated as a novel antiasthametic 
agents. 27 Ooe T. et al.28 synthesized indazoles which have been found to possess varied 
biological activities such as hematinics, immunostimulants and antitumor agents. The 
remarkable cytotoxic activities of indazoles have been reported.29 some indazoles (IV) 
have been synthesized by Duzinska-Usarewicz et al.30 and found to possess 
antiinflammatory activity. Effland R. et al.31 synthesized 3-(pyridyl amino)-indazoles (V) 
and reported as antidepressant and anxiolytics. 
 
                          
N
N
H
R
R1
(IV)
NNH
NH
N
(V)
 
 
           Newshaw R. and coworkers32 have prepared 4-amino ethoxy indazoles and 
reported them as dopamine D2 agonists. Kania R. et al.33 have synthesized indazole 
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derivatives as protein kinase inhibitors. Indazole derivatives are reported as inhibitors of 
cell proliferation.34 The remarkable antipsychotic activity35 of indazoles (VI) have been 
reported.  
 
       
O
O
N
NH
R1
CH3
R
(VI) Where, Z = Unsubstituted piperazine,Pyridino, etc.  
 
          Lavielle G. et al.36 prepared [(pyrolidinyl) methyl]-indazoles and suggested them 
for the treatment of migrains. Marfat Anthony37 has patented indazole derivatives as 
phosphodiesterase and tumor necrosis factor production inhibitors. Indazole derivatives 
have been evaluated as α,β-adrenoreceptor agonists.38 Antiviral activity39 of indazoles 
have been reported. Badran M. et al.40 synthesized some novel indazole derivatives by 
fusing with triazines and triazoles for exploring their antiinflammatory activity.          
Moreover, Hwang I. T. et al.41 have synthesized some new 2-Phenyl-4,5,6,7-tetrahydro-
2H-indazole derivatives as paddy field herbicides. Tanitame A. et al.42 have reported the 
designed, synthesized and studied structure-activity relationship of novel indazole 
analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity (VII). Nasr 
M. N. et al.43 have prepared some novel 3,3a,4,5,6,7-Hexahydroindazole and 
Arylthiazolylpyrazoline derivatives as anti-inflammatory agents. Pinna G. A. et al.44 have 
described the synthesis of chromophore-modified bis-benzo[g]indole carboxamides. 
Recently, Abouzid K. A. et al.45 have synthesized and demonstrate anti-inflammatory 
activity of novel indazolones. Wang Q. et al.46,47 have described the synthesis and 
herbicidal activity of 2-Cyano-3-substituted-pyridinemethylaminoacrylates. Kakimoto T. 
et al.48 have prepared some novel 3,3a,5,9b-Tetrahydro-2H-furo[3,2-c][2]benzopyran 
derivatives of chiral glycol benzyl ether herbicides. Ikeguchi M. et al.49 have documented 
the synthesis and herbicidal activity of new oxazinone herbicides with a long-lasting 
herbicidal activity against Echinochloa oryzicola.  
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(VII)  
 
          Among variety of pharmacological properties have been encountered with indazole 
systems, keeping the above in mind some novel indazole derivatives have been 
synthesized which have been described as under. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL EVALUATION OF ETHYL-4-
ARYL-6-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-
2-OXO-CYCLOHEX-3-ENE-CARBOXYLATES  
 
SECTION-II: SYNTHESIS AND BIOLOGICAL EVALUATION OF METHYL-4-
ARYL-6-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-
2-OXO-CYCLOHEX-3-ENE-CARBOXYLATES  
 
SECTION-III: SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-
[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2,3,3a- 
,4,5-PENTAHYDROINDAZOLE-3-ONES   
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SECTION – I  
SYNTHESIS AND BIOLOGICAL EVALUATION OF ETHYL-4-ARYL-6-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-OXO-CYCLOHEX-3-ENE-
CARBOXYLATES  
 
          Cyclohexenones are endowed with variety of pharmacodynamic activities such as 
anticonvulsant, antidiabatic etc. Looking to the interesting properties of cyclohexenones 
aroused considerable interest to synthesis of Ethyl-4-aryl-6-[4’-(p-chlorobenzyloxy)-3’-
methoxyphenyl]-2-oxo-cyclohex-3-ene- carboxylates of the type (IX) by the 
cyclocondensation of 1-Aryl-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-propenones 
with ethylacetoacetate in the presence of anhydrous K2CO3 in order to study their 
biodynamic behavior. 
      
O
O
CH3
Cl
O
R
O
Cl
R O
O
O CH3
O
H3C
K2CO3
CH3COCH2COOC2H5
Type(I) R=ArylType(IX)
 
 
          The structure elucidation of synthesized compounds has been done on the basis of 
Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry. Purity of all compounds have been checked by 
thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
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bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs.  
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IR SPECTRAL STUDIES OF ETHYL-4-(p-METHOXYPHENYL)-6-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-OXO-CYCLOHEX-3-ENE-
CARBOXYLATE 
 
 Instrument : Spectrum One 69888 Spectroph otometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2956.21 2975-2950 A 
-CH3 C-H str. (sym.) 2876.21 2880-2860 “ 
 C-H def. (asym.) 1465.97 1470-1435 “ 
Aromatic C-H str. 3049.33 3090-3030 “ 
 C=C str. 1514.93 1540-1480 “ 
 C-H i.p. (def.) 1101.27 1125-1090 “ 
 C-H o.o.p. (def.) 833.81 835-810 “ 
Methoxy C-O str. 1254.91 1260-1200 “ 
Halide C-Cl str. 637.96 800-600 “ 
Ether Ar-O-C str. 1234.61 1260-1200 “ 
Cyclohexenone C=O str. 1696.72 1720-1690 “ 
 C=C str. 1570.01 1580-1520 “ 
Ester C=O str. 1725.32 1750-1725 “ 
O
Cl
O
CH3
O
O
OCH3
O
H3C
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NMR SPECTRAL STUDIES OF ETHYL-4-(p-METHOXYPHENYL)-6-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-OXO-CYCLOHEX-3-ENE-
CARBOXYLATE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1. 1.05 t 3 7.12 9 
2. 2.66 dd 1 16.23 5a 
3. 2.74 dd 1 16.32 5b 
4. 3.06 qt 1 17.67 6 
5. 3.72 d 1 3.00 1 
6. 3.84 s 3 -- 7” 
7. 3.88 s 3 -- 7’ 
8. 4.00 q 2 7.10 8 
9. 5.10 s 2 -- 8’ 
 
10. 6.47-7.57 m 12 -- 
3,2’,3’,6’,10’
,11’,13’,14’,
2”,3”,5”,6”, 
Total No. of protons  29 
 
 
O
Cl
O
CH3
O
O
OCH3
O
H3C 1 2
3
45
6
7
8
9
1'
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4'
5' 6'
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MASS SPECTRAL STUDIES OF ETHYL-4-(p-METHOXYPHENYL)-6-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-2-OXO-CYCLOHEX-3-ENE-CARBOXYLATE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
Cl
O
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O
OCH3
O
H3C
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MASS FRAGMENTATION 
[Base peak]
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF ETHYL-4-ARYL-6-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-OXO-CYCLOHEX-3-ENE-
CARBOXYLATES 
 
(A) Synthesis of 1-Aryl-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-propenones 
      See  [A],Part-I, Section-I (B). 
 
(B) Preparation of Ethyl-4-(p-methoxyphenyl)-6-[4’-(p- chlorobenzyloxy)-3’-met-    
hoxyphenyl]-2-oxo-cyclohex-3-ene-carboxylate 
          To a solution of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphen- 
yl]-propenones (4.08g,0.01M)) in dry acetone, anhydrous K2CO3(5.52g,0.04M)) and 
ethyl acetoacetate(2.55ml,0.02M) was added and the reaction mixture was stirred at room 
temperature for overnight and was filtered. The solvent from the filtrate on distill off 
gave a solid, which was crystallized from methanol to gave desired product .Yield 45%, 
m.p.1760C, (C30H29ClO6; Required: C, 69.16; H,5.61; N, 0; Found: C, 68.92 ; H, 5.65; 
N,0 %) Similarly, other Ethyl-4-aryl-6-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-2-
oxo-cyclohex-3-ene-carboxylates were prepared. The physical data are recorded in Table 
No.9 
 
(C)  Biological evaluation of Ethyl-4-aryl-6-[4’-(p-chlorobenzyloxy)-3’-methoxyphe- 
nyl]-2-oxo-cyclohex-3-ene-carboxylates 
          Antimicrobial testing were carried out as described in [A], Part-I, Section-I (C). 
The zones of inhibition of test solutions are recorded in Graphical Chart No.9 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Ethylcyclohexenone derivatives tested 
compounds 9a,9g,9i and 9k showed greater degree of antibacterial activity against 
B.coccus. However, the compounds 9b,9e,9i and 9j showed greater degree of 
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antibacterial activity against B.subtilis. The compounds 9a,9e,9g  and 9j showed greater 
degree of antibacterial activity against E.coli. However, the compounds 9b,9d,9e and 9i 
showed greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Ethylcyclohexenone derivatives tested 
compounds 9c,9d,9h and 9j showed greater degree of antifungal activity against  A.niger. 
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TABLE NO. 9: PHYSICAL CONSTANTS OF ETHYL-4-ARYL-6-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHEN- 
YL]-2-OXO-CYCLOHEX-3-ENE-CARBOXYLATES 
Comp. 
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent
System
10 
Calcd. 
8
Found 
9 
9a -C6H5 C29H27ClO5 490.50 175 0.56 55 -- -- S1 
9b -4-OCH3-C6H4 C30H29ClO6 521.00 176 0.55 45 -- -- S1 
9c -4-Cl-C6H4 C29H26Cl2O5 525.00 166 0.47 66 -- -- S1 
9d -2,4-(Cl)2-C6H3 C29H25Cl3O5 559.50 210 0.42 63 -- -- S2 
9e -4-OH-C6H4 C29H27ClO6 506.50 216 0.34 52 -- -- S2 
9f -4-Br-C6H4 C29H26BrClO5 569.50 196 0.46 48 -- -- S1 
9g -4-NO2-C6H4 C29H26ClNO7 535.50 180 0.34 70 2.61 2.68 S2 
9h -4-NH2-C6H4 C29H28ClNO5 505.50 186 0.34 68 2.77 2.69 S2 
9i -2-OH-C6H4 C29H27ClO6 506.50 186 0.34 65 -- -- S2 
9j -4-CH3-C6H4 C30H29ClO5 505.00 175 0.56 66 -- -- S1 
9k -2,4-(OCH3)2-C6H3 C31H31ClO7 551.00 210 0.55 52 -- -- S1 
9l -4-(O-CH2-C6H5)-C6H4 C36H33ClO6 597.00 190 0.47 50 -- -- S2 
TLC Solvent system : S1 : Methanol:Dichloromethane(0.4:9.6); S2 : Ethyl acetate : Hexane(40:60) 
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GRAPHICAL CHART NO. 9: ANTIMICROBIAL ACTIVITY OF ETHYL-4-ARYL-6-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-2-OXO-CYCLOHEX-3-ENE-CARBOXYLATES 
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B.coccus 19 14 11 14 12 12 18 15 17 15 17 10 20 21 18 20 0
B.subtilis 14 22 13 14 18 9 14 17 23 18 14 14 24 24 17 18 0
E.coli 22 12 15 16 19 17 22 14 17 23 12 11 22 25 24 18 0
P.vulgaris 12 16 13 18 17 12 15 15 17 13 10 12 21 25 25 15 0
A.niger 14 12 18 21 17 15 16 19 16 22 14 18 0 0 0 0 24
9a 9b 9c 9d 9e 9f 9g 9h 9i 9j 9k 9l Ampicillin
Amoxi
cillin
Norflo
xacin
Benzyl 
Penicil
lin
Griseo
fulvin
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SECTION – II 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF METHYL-4-ARYL-6-[4’-
(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-OXO-CYCLOHEX-3-
ENE-CARBOXYLATES 
 
          Cyclohexenones are endowed with variety of pharmacodynamic activities such as 
anticonvulsant, antidiabatic etc. Looking to the interesting properties of cyclohexenones 
aroused considerable interest to synthesize of Methyl-4-aryl-6-[4’-(p-chlorobenzyloxy)-
3’-methoxyphenyl]-2-oxo-cyclohex-3-ene-carboxylates of the type (X) by the 
cyclocondensation of 1-Aryl-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-propenones 
with methylacetoacetate in the presence of anhydrous K2CO3 in order to study their 
biodynamic behaviour. 
 
       
O
O
CH3
Cl
O
R
O
Cl
R O
O
O
CH3
O
H3C
K2CO3
CH3COCH 2COOCH 3
Type(I) R=ArylType(X)
 
 
          The structure elucidation of synthesized compounds has been done on the basis of 
Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry. Purity of all compounds have been checked by 
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thin layer chromatography.All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs.  
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IR SPECTRAL STUDIES OF METHYL-4-(p-METHOXYPHENYL)-6-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-OXO-CYCLOHEX-3-ENE-
CARBOXYLATE 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2966.21 2975-2950 A 
-CH3 C-H str. (sym.) 2866.21 2880-2860 “ 
 C-H def. (asym.) 1455.97 1470-1435 “ 
Aromatic C-H str. 3039.33 3090-3030 “ 
 C=C str. 1515.93 1540-1480 “ 
 C-H i.p. (def.) 1101.27 1125-1090 “ 
 C-H o.o.p. (def.) 832.81 835-810 “ 
Methoxy C-O str. 1252.91 1260-1200 “ 
Halide C-Cl str. 667.96 800-600 “ 
Ether Ar-O-C str. 1244.61 1260-1200 “ 
Cyclohexenone C=O str. 1697.72 1720-1690 “ 
 C=C str. 1570.01 1580-1520 “ 
Ester C=O str. 1726.32 1750-1725 “ 
O
Cl
O
CH3
O
O
OCH3
O
H3C
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NMR SPECTRAL STUDIES OF METHYL-4-(4-METHOXYPHENYL)-6-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-OXO-CYCLOHEX-3-ENE-
CARBOXYLATE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1. 2.70 dd 1 16.02 5a 
2. 2.84 dd 1 16.28 5b 
3. 3.04 qt 1 8.70 6 
4. 3.36 d 1 10.30 1 
5. 3.84 s 6 -- 7”,8 
6. 3.89 s 3 -- 7’ 
7. 5.11 s 2 -- 8; 
8. 6.47 s 1 -- 3 
 
9. 6.77-7.54 m 11 -- 
2’,3’,6’,10’,11
’,13’,14’,2”,3”
,5”,6”, 
Total No. of protons  27 
 
O
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MASS SPECTRAL STUDIES OF METHYL-4-(p-METHOXYPHENYL)-6-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-2-OXO-CYCLOHEX-3-ENE-CARBOXYLATE 
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MASS FRAGMENTATION 
[Base  peak]
M/z : 396.14
M/z :448.14
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF METHYL-4-ARYL-6-[4’-
(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2-OXO-CYCLOHEX-3-E-
NE-CARBOXYLATES 
 
(A) Synthesis of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]- 
propenones 
       See [A],Part-I, Section-I (B). 
 
(B) Preparation of Methyl-4-(p-methoxyphenyl)-6-[4’-(p-chlorobenzyloxy)-3’-meth- 
oxyphenyl]-2-oxo-cyclohex-3-ene-carboxylate 
          A solution of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]- 
propenones (4.08g,0.01M)) in dry acetone, anhydrous K2CO3(5.52g,0.04M)) and methyl 
acetoacetate(2.15ml,0.02M) was added and the reaction mixture was stirred at room 
temperature for overnight and was filtered. The solvent from the filtrate on distill off 
gave a solid, which was crystallized from methanol to gave desired product .Yield 45%, 
m.p.1800C, (C29 H27ClO6; Required: C,68.70; H,5.37; N, 0; Found: C, 68.90 ; H, 5.52; 
N,0 %) Similarly, other Methyl-4-aryl-6-[4’-(p- chlorobenzyloxy)-3’-methoxyphenyl]-2-
oxo-cyclohex-3-ene- carboxylates were prepared. The physical data are recorded in Table 
No.10 
 
(C) Biological evaluation of Methyl-4-aryl-6-[4’-(p-chlorobenzyloxy)-3’-
methoxyphen- yl]-2-oxo-cyclohex-3-ene-carboxylates  
           Antimicrobial testing were carried out as described in [A],Part-I, Section-I (C). 
The zones of inhibition of test solutions are recorded in Graphical Chart No.10 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Methylcyclohexenone derivatives tested 
compounds 10c,10g,10h and 10k showed greater degree of antibacterial activity against 
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B.coccus. However, the compounds 10e,10h,10i and 10j showed greater degree of 
antibacterial activity against B.subtilis. The compounds 10a,10d,10e and 10j showed 
greater degree of antibacterial activity against E.coli. However, the compounds 
10c,10d,10h and 10i showed greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Methylcyclohexenone derivatives tested 
compounds 10a,10c,10h and 10i showed greater degree of antifungal activity against  
A.niger. 
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TABLE NO.10: PHYSICAL CONSTANT OF METHYL-4-ARYL-6-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHEN- 
YL]-2-OXO-CYCLOHEX-3-ENE-CARBOXYLATES 
Comp. 
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular 
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent
System
10 
Calcd.
8
Found
9
10a -C6H5 C28H25ClO5 476.50 172 0.68 55 -- -- S1 
10b -4-OCH3-C6H4 C29H27ClO6 506.50 180 0.56 45 -- -- S1 
10c -4-Cl-C6H4 C28H24Cl2O5 511.00 171 0.56 66 -- -- S1 
10d -2,4-(Cl)2-C6H3 C28H23Cl3O5 545.50 190 0.60 63 -- -- S1 
10e -4-OH-C6H4 C28H25ClO6 492.50 210 0.38 52 -- -- S2 
10f -4-Br-C6H4 C28H24BrClO5 555.50 182 0.56 48 -- -- S1 
10g -4-NO2-C6H4 C28H24ClNO7 521.50 190 0.32 70 2.68 2.72 S2 
10h -4-NH2-C6H4 C28H26ClNO5 491.50 176 0.36 68 2.85 2.90 S2 
10i -2-OH-C6H4 C28H25ClO6 492.50 180 0.38 65 -- -- S2 
10j -4-CH3-C6H4 C29H27ClO5 490.50 170 0.60 66 -- -- S1 
10k -2,4-(OCH3)2-C6H3 C30H29ClO7 537.00 200 0.56 52 -- -- S1 
10l -4-(O-CH2-C6H5)-C6H4 C35H31ClO6 583.00 196 0.45 50 -- -- S2 
TLC Solvent system : S1 : Methanol:Dichloromethane(0.4:9.6), S2 : Ethyl acetate : Hexane(40:60) 
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GRAPHICAL CHART NO. 10: ANTIMICROBIAL ACTIVITY OF METHYL-4-ARYL-6-[4’-(p-CHLOROBENZYLOXY)-
3’-METHOXYPHENYL]-2-OXO-CYCLOHEX-3-ENE-CARBOXYLATES 
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B.coccus 13 14 15 14 14 12 19 15 14 15 18 11 20 21 18 20 0
B.subtilis 14 15 13 14 18 9 14 17 23 18 14 14 24 24 17 18 0
E.coli 20 12 15 18 19 17 18 14 10 20 12 11 22 25 24 18 0
P.vulgaris 12 16 20 18 14 12 14 22 17 13 10 12 21 25 25 15 0
A.niger 19 12 22 14 17 15 16 19 21 13 14 18 0 0 0 0 24
10a 10b 10c 10d 10e 10f 10g 10h 10i 10j 10k 10l Ampicill
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Amoxicil
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Penicillin
Griseofu
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SECTION – III 
  
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2,3,3a,4,5-PENTAHYDROIN- 
DAZOLE-3-ONES  
 
          The synthesis of indazole has attracted the attention of chemists because of their 
potential pharmcodynamic properties. Looking to the interesting properties of indazoles, 
it appeared of interest to synthesize a series of 6-Aryl-4-[4’-(p-chlorobenzyloxy)-3’-
methoxyphenyl]-2,3,3a,4,5-pentahydroindazole-3-ones of type (XI) for obtaining 
biologically potent agents, which were prepared by reacting Methyl-4-aryl-6-[4’-(p-
chlorobenzyloxy)-3’-methoxyphenyl]-2-oxo-cyclohex-3-ene-carboxylates of the type (X) 
with hydrazine hydrate in presence of glacial acetic acid. 
 
                                         
 
         
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
       The structure elucidation of synthesized compounds has been done on the basis of 
Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
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further supported by Mass spectrometry. Purity of all compounds have been checked by 
thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs.  
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IR SPECTRAL STUDIES OF 6-(p-METHOXYPHENYL)-4-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2,3,3a,4,5-PENTAHYDROIN- 
DAZOLE-3-ONE 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2956.47 2975-2950 A 
-CH3 C-H str. (sym.) 2862.83 2880-2860 “ 
 C-H def. (asym.) 1464.55 1470-1435 “ 
Aromatic C-H str. 3035.26 3090-3030 “ 
 C=C str. 1512.93 1540-1480 “ 
 C-H i.p. (def.) 1165.87 1177-1027 “ 
 C-H o.o.p. (def.) 820.53 835-810 “ 
Methoxy C-O str. 1248.50 1260-1200 “ 
Halide C-Cl str. 747.93 800-600 “ 
Ether Ar-O-C str. 1232.51 1260-1200 “ 
Cyclohexenone C=C str. 1575.14 1580-1550 “ 
Imidazole ring C=O str. 1655.97 1760-1655 “ 
 N-H str. 3356.33 3440-3300 “ 
 C=N str. 1602.97 1650-1580 “ 
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NMR SPECTRAL STUDIES OF 6-(p-METHOXYPHENYL)-4-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2,3,3a,4,5-PENTAHYDROIN- 
DAZOLE-3-ONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1. 2.22 dd 1 15.76 5a 
2. 2.69 dd 1 15.47 5b 
3. 2.85 qt 1 16.96 4 
4. 3.11 d 1 4.24 3a 
5. 3.81 s 3 -- 7” 
6. 3.90 s 3 -- 7’ 
7. 5.11 s 2 -- 8’ 
8. 5.22 b 1 -- 2 
 
9. 6.58-7.48 m 12 -- 
7,2’,3’,6’,10’
,11’,13’,14’,
2”,3”,5”,6”, 
Total No. of protons  25 
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MASS SPECTRAL STUDIES OF 6-(p-METHOXYPHENYL)-4-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-
2,3,3a,4,5-PENTAHYDROINDAZOLE-3-ONE 
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                              MASS FRAGMENTATION 
[Base peak]
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EXEPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-[4’-(p-
CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-2,3,3a,4,5-PENTAHYDROIN- 
DAZOLE-3-ONES 
 
(A) Synthesis of 1-(p-Methoxyphenyl)-3-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
propenones 
       See [A],Part-I, Section-I (B), 
 
(B)   Preparation of Methyl-4-(p-Methoxyphenyl)-6-[4’-(p-chlorobenzyloxy)-3’-
methoxyphenyl]-2-oxo-cyclohex-3-ene-carboxylates 
        See [A],Part-IV, Section-II (B). 
 
(C) Preparation of 6-(p-Methoxyphenyl)-4-[4’-(p-chlorobenzyloxy)-3’-methoxyp-  
henyl]-2,3,3a,4,5-pentahydroindazole-3-one 
          To a solution of Methyl-4-(p-methoxyphenyl)-6-[4’-(p-chlorobenzyloxy)-3’-
methoxyphenyl]-2-oxo-cyclohex-3-ene- carboxylate (5.06g,0.01M) in ethanol (20 ml), 
hydrazine hydrate (2.5ml,0.05M) and acetic acid (catalytic amount) was added. The 
content was refluxed at 800 C for 10 hr on water bath. The residue obtained after cooling 
was filtered and isolated. The product was crystallized from methanol. Yield 55 %, m. p. 
153o C. (C28 H25ClN2O4; Required: C,68.78; H,5.15; N, 5.73; Found: C, 68.90 ; H, 5.32; 
N,5.68 %). Similarly other, 6-Aryl-4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
2,3,3a,4,5-pentahydroin-dazole-3-ones were prepared. The physical data are recorded in 
Table No. 11 
 
(C) Biological evaluation of 6-Aryl-4-[4’-(p-chlorobenzyloxy)-3’-methoxyphenyl]-
2,3,3a,4,5-pentahydroindazole-3-ones 
          Antimicrobial testing was carried out as described in [A], Part-I, Section-I (C). The 
zones of inhibition of test solutions are recorded in Graphical Chart No.11 
 
CONCLUSION 
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Antibacterial activity 
           The screening data indicated that among Indazole derivatives tested compounds 
11a,11b,11f and 11g showed greater degree of antibacterial activity against B.coccus. 
However, the compounds 11a,11b,11i and 11j showed greater degree of antibacterial 
activity against B.subtilis. The compounds 11c,11g,11j  and 11l showed greater degree of 
antibacterial activity against E.coli. However, the compounds 11a,11b,11e and 11g 
showed greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Indazole derivatives tested compounds 
11a,11e,11h and 11l showed greater degree of antifungal activity against  A.niger. 
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TABLE NO.11 :  PHYSICAL CONSTANTS OF 6-ARYL-4-[4’-(p-CHLOROBENZYLOXY)-3’-METHOXYPHENYL]-
2,3,3a,4,5-PENTAHYDROINDAZOLE-3-ONES 
Comp. 
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular 
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent
System
10 Calcd. 8
Found
9 
11a -C6H5 C27H23ClN2O3 458.50 144 0.60 55 6.10 6.15 S1 
11b -4-OCH3-C6H4 C28H25ClN2O4 488.50 153 0.46 56 5.73 5.80 S1 
11c -4-Cl-C6H4 C27H22Cl2N2O3 493.00 150 0.50 68 5.68 5.72 S1 
11d -2,4-(Cl)2-C6H3 C27H21Cl3N2O3 527.50 163 0.56 57 5.31 5.40 S1 
11e -4-OH-C6H4 C27H23ClN2O4 474.50 190 0.50 55 5.90 5.85 S1 
11f -4-Br-C6H4 C27H22BrClN2O3 537.50 180 0.42 46 5.21 5.25 S2 
11g -4-NO2-C6H4 C27H22ClN3O5 503.50 186 0.42 55 8.34 8.40 S2 
11h -4-NH2-C6H4 C27H24ClN3O3 473.50 190 0.30 47 8.87 8.80 S2 
11i -2-OH-C6H4 C27H23ClN2O4 474.50 186 0.50 42 5.90 5.95 S1 
11j -4-CH3-C6H4 C28H25ClN2O3 472.50 180 0.63 66 5.92 5.90 S1 
11k -2,4-(OCH3)2-C6H3 C29H27ClN2O5 518.50 166 0.57 65 5.40 5.42 S1 
11l -4-(O-CH2-C6H5)-C6H4 C34H29ClN2O4 565.00 180 0.44 52 4.96 4.90 S2 
TLC Solvent system : S1 :  Methanol:Dichloromethane(0.4:9.6); S2 : Ethyl acetate : Hexane(40:60) 
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GRAPHICAL CHART NO. 11 : ANTIMICROBIAL ACTIVITY OF 6-ARYL-4-[4’-(p-CHLOROBENZYLOXY)-3’-
METHOXYPHENYL]-2,3,3a,4,5-PENTAHYDROINDAZOLE-3-ONES 
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B.coccus 19 18 12 16 14 19 18 16 17 16 12 17 20 21 18 20 0
B.subtilis 22 21 15 12 19 17 12 19 22 23 14 18 24 24 17 18 0
E.coli 21 20 23 18 19 12 22 17 11 22 19 22 22 25 24 18 0
P.vulgaris 20 22 14 16 20 17 20 15 14 13 11 14 21 25 25 15 0
A.niger 22 10 17 18 20 20 10 22 17 12 20 22 0 0 0 0 24
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[B] STUDIES ON SCHIFF’S BASE DERIVATIVES 
 
PART-I : STUDIES ON SCHIFF’S BASE DERIVATIVES 
 
INTRODUCTION  
 
          Schiff’s base derivatives have been found to be potent drug in pharmaceutical 
industries and possess a wide spectrum of biology activity. Azomethines are also known 
as Schiff's bases and they are well known intermediate for the preparation of azetidinone, 
thiazolidinone, formazan, arylacetamide and many other derivatives. These are the 
compounds containing characteristic –C = N – group. 
          Azomethines are obtained mainly by heating the aldehyde & aromatic amine 
together. However, it is sometimes more convenient to work in a solvent such as alcohol, 
dilute acetic acid or glacial acetic acid. Sometimes the reaction is aided by trace of acid; 
in other cases the hydrochloride of the amines can be used in the synthesis. In general 
schiff's bases do not react further with either of the reagent used for their preparation, as 
do most of the other types of simple intermediates. 
 
SYNTHETIC ASPECTS 
 
          Several methods 1-11 for the preparation of azomethine derivatives are documented 
in literature. 
   1. General account of the summary of reaction of aldehydes with amine. 
 
   
R
O
H
+ R1 NH2 R N R1
 
 
  2. Imine formation involves two steps. 
(a) Addition of the amine to the carbonyl group of the aldehyde gives aldol. The aldol is 
rarely capable of isolation. 
   
R
O
H
+ R1 NH2 R NHR1
OH  
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(b) The loss of water to give an imine (azomethine), this corresponds to the 
“crotonaldehyde stage” of the aldol condensation. 
            
+R NHR1
OH
R N R1
H2O
 
  
 
THERAPEUTIC IMPORTANCE 
           
            Smalders et. al.12 documented some new azomethines like benzylidene 
napthylamine which  give potential antitumor   reagent phosphonates. Nagamatsu et. al.13 
have prepared some azomethines (I) by the condensation of 4–Mercapto–1H–pyrazolo-
[3,4-d]-pyrikidine-6(7H)-one with hydrazine hydrate to give (I), useful as xanthine 
oxixase inhibitor                                                                                                                      
              
         
N
H
N
N
N
H
N
NR1 R
O
(I)
N
N
N
N SH
CH3
N
N
N
NSH
CH3
(II)
Where, R=alkyl, aryl        R1=H,Me
 
            
          Yadawe M. S. and Patil S. A.14 have prepared azomethines (II) which were 
screened for their antibacterial and antifungal activities. 
           A series of 4-[5-(Halophenyl)-2-furfurylidene]-amino-3-mercapto-5-substituted-
1,2,4-triazoles were synthesized by Holla B. et. al.15 and reported their antibacterial 
activity. 
           Mehta R. H. et. al.16 have synthesised coumarin azomethine derivatives and 
reported their antibacterial activity. Khalafallah A. and Hassan M.17 have suggested some 
styryl Schiff’s bases as potential antibacterial and antifungal agents. Sharat El-Din and 
Nabaweya18 have described compounds having good antibacterial activity. 
                                                                                                                                                                            
 189
           Chohan et. al.19 have reported azomethines of type (III), which have been screened 
and compared for their antibacterial action against bacterial species. 
N
N
N X
(III)
N
N NH N
N
O R2
CH3
X
R1
Ph
(IV)
Where, X=O,S
Where, R1=H,Me      
 R2=H,Ph
X=PhN, 4-MeOC6H4N,4-O2NC6H4N  
         
           De Boplab and co-workers20 have synthesised azomethines (IV) by condensation 
of (imidazolinylamino) pyrazole carboxaldehydes with arylamines. Some of them were 
found to exhibit significant antibacterial and antifungal activities. Desmukh M.D. and 
Doshi A.21 have synthesized some new azomethines show good antimicrobial activity 
against test organism. 
          Wang, Yangang and co-workers22 have screened some azomethines having good 
plant hormone activity. Das and co-workers23 have prepared Schiff's base of 
aminohydroxyguanidine (SB-ASHGS) & were tested for antiviral activity against herpes 
simplex virus type 1 (HSV–1) and adenovirus type 5 (Ad5) alone with other heterocyclic 
SB-AHGS. Solankee Anjani et. al.24 have suggested addition of 3,4,5-
Trimethoxybenzaldehyde to 4-Thiazolidinones resulted in benzylidene derivatives having 
potential antibacterial activity. 
          Ram Tilak et. al.25 have synthesised some Schiff's bases, thiazolidinones A2-
triazolines and formazans bearing 2-Chlorophenothiazines and screened against 
carrageenin induced edema in albino rats. The thiazolidinones showed promising anti-
inflammatory activity. Cascaval Alexandru; et. al.26 have synthesised azomethine of type 
(V) which exhibited antipyretic properties. 
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N
N
N
R
O
Ph
CH3
CH3
OH
R1
R2
(V)
Where, R=H,Me   R1,R2=H,Cl
 
           
          Ali, Yousif et. al.27 have reported some Schiff’s base derivatives of glucose contg. 
acetylenic bond were also prepared hydroxybenzaldehydes were first converted to o-
prop-2-ynyl-benzaldehyde followed by their condensation with glucosamine. The 
compounds possess bactericidal activity. Pandeya S.N.. et. al.28 have prepared Schiff's 
base showing good activity against vibrio cholerae. 
         Omar  et. al.29 have described cyclocondensation of azomethines having good 
antischistosomal activity. Pawar R. P. et. al.30 have synthesised azomethines by the 
condensation of iodovanillin with different substituted aromatic amines showing good 
antibacterial activity. A novel class of acetyl ferrocene derived from Schiff's bases 
possess antimicrobial activity by Chohan and co-workers31. Holla B. S. et. al. 32 have 
documented azomethine (VI) bearing triazole moiety which possess good antibacterial 
activity. Ergenc and co-workers33 have synthesized azomethine derivatives (VII) showing 
antifungal activity.  
 
    
N
N N
SH
N
Ar
N
NN
SH
N
Ar
R
n
(VI)
O
N N
H
N
N
R
S
(VII)           R=Aryl
 
 
          Holla B. S. et. al. 34 have prepared Mannich base of type (VIII) as under. 
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N
N
N
SR1
CH3
N
O
NO2
(VIII)
Where, R,R1=Aryl
 
           
         B. Shivrama et. al.35 have synthesized azomethines which were found to possess 
antibacterial and anti-inflammatory activity. Pascal Rathelst et. al.36 have reported some 
new azomethines as antiparasitic agents. Adnan A. et. al.37 studied the anti-inflammatory 
activity of some azomethines Dimmock J. et. al.38 have suggested azomethines as 
cytotoxic agent. 
         Thus with an effort to capitalize the biological potential of the heterocyclic system 
and to provide more interesting compounds for biological study, we have undertaken the 
synthesis of azomethines bearing triazole moiety. 
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SECTION – I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF N-ARYL-1,-4-(p-
CHLOROBENZYLOXY)-3-METHOXYPHENYL-1-YL-AZOMETHINES 
 
         N-Aryl-1,-4-(p-chlorobenzyloxy)-3-methoxyphenyl-azomethines of type (XII) have 
been prepared by the condensation of 4-(p-Chlorobenzyloxy)-3-methoxybenzaldehyde 
with amine in presence of glacial acetic acid as shown under. 
                   
HO
O
O
CH3
Cl
+
gla. aceticacidR
NH2
N
O
O
CH3
Cl
R
Type(XII)Type(XII) R=Aryl     
          
              The structure elucidation of synthesized compounds has been done on the basis 
of Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry. Purity of all compounds have been checked by 
thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs.  
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O
O
HO
Cl
NH2
R
O
O
Cl
N
R
R=ArylType(XII)
REACTION SCHEME
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IR SPECTRAL STUDIES OF N-(p-THIOMETHOXYPHENYL)-1,-4-(p-CHLOR-
OBENZYLOXY)-3-METHOXYPHENYL-1-YL-AZOMETHINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2961.12 2975-2950 A 
-CH3 C-H str. (sym.) 2867.60 2880-2860 “ 
 C-H def. (asym.) 1465.33 1470-1435 “ 
Aromatic C-H str. 3074.75 3090-3030 “ 
 C=C str. 1508.35 1540-1480 “ 
 C-H i.p. (def.) 1109.44 1125-1090 “ 
 C-H o.o.p. (def.) 826.21 835-810 “ 
Methoxy C-O str. 1230.46 1260-1200 “ 
Halide C-Cl str. 750.94 800-600 “ 
Ether Ar-O-C str. 1214.35 1260-1200 “ 
Imine C=N str. 1574.20 1580-1550 “ 
 
N
O
O
CH3
Cl
S
CH3
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NMR SPECTRAL STUDIES OF    N-(p-THIOMETHOXYPHENYL)-1,-4-(p-
CHLOROBENZYLOXY)-3-METHOXYPHENYL-1-YL-AZOMETHINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
 No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1 2.5 s 3 -- 8 
2. 3.98 s 3 -- 7” 
3. 5.18 s 2 -- 1’ 
4. 7.14-7.62 m 11 -- 
2,5,6,3’,4’,6’
,7’,2”,3”,5”,
6” 
5. 8.35 s 1 -- 7 
Total No. of protons  20 
 
 
1
2
34
5
6
7
8
1'
2'
3'
4'
5'
6'
7'
N
O
O
CH3
Cl
S
CH3
1"
2" 3"
4"
5"6"
7"
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MASS SPECTRAL STUDIES OF N-(p-THIOMETHOXYPHENYL)-1,-4-(p-CHLOR-OBENZYLOXY)-3-
METHOXYPHENYL-1-YL-AZOMETHINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
O
O CH3
Cl
S
CH3
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MASS FRAGMENTATION 
[Base peak]
M/z : 351.10
M/z :287.09
M/z : 248.06
M/z : 227.09
M/z : 151.06
M/z : 139.04
M/z : 142.1
+
o
+
o
+
o
+
o
+
o+o
+
o
OH
Cl
M/z :363.12
+
o
N
O
O CH3
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CH3
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O
O CH3
S
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O CH3
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O CH3
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O CH3
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O CH3
N
O
O CH3
CH3
S
CH3
NH2 S
CH3
N
O
O CH3
CH3
CH
S
CH3
M/z : 276.37CH2
CH3
N
CH
SH
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+
o
+
o
M/z : 397.09
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF N-ARYL-1,-4-(p-CHLOR-
OBENZYLOXY)-3-METHOXYPHENYL-1-YL-AZOMETHINES 
 
(A) Synthesis of 4-(p-Chlorobezyloxy)-3-methoxybenzaldehyde 
 
          The solution of Vaniline (1.53g, 0.01M) in DMF ( 7.7ml) was heated at 50-550C    
in presence of 4-chlorobenzoyl chloride(1.75g, 0.01) and K2CO3(2.76gm, 0.02) for 5 hrs, 
after 5 hrs product was precipitated by water addition. The separated solid was filtered 
and leached in Methanol.Yield 90%, m.p.110 oC. 
 
(B) Synthesis of N-(p-Thiomethoxyphenyl)-1,-4-(p-chlorobenzyloxy)-3-methoxyphe- 
nyl-1-yl-azomethine 
          Mixture of 4-(p-Chlorobezyloxy)-3-methoxybenzaldehyde (2.76g, 0.01M)  and p- 
Thiomethoxyaniline (1.39g, 0.01M) in ethanol(10v) was refluxed in presence of glacial  
acetic acid for 10 hr. The separated solid was filtered out and crystallized from  ethanol. 
Yield 48 %, m.p 2150 C. (C25 H21ClN2O4; Required: C,66.89; H, 4.72; N, 6.24; Found: C, 
66.70 ; H, 4.82; N,6.21 %. Similarly, other N-Aryl-1,-4-(p-chlorobenzyloxy)-3-
methoxyphenyl-1-yl-azomethines were prepared. The physical data are recorded in Table 
No. 12. 
 
(C) Biological evaluation of N-Aryl-1,-4-(p-chlorobenzyloxy)-3-methoxyphenyl-1-yl-
azomethines 
          Antimicrobial testing were carried out as described in [A],Part-I, Section-I(C). The 
zones of inhibition of test solutions are reported in Graphical Chart No. 12. 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Schiff’s base derivatives tested 
compounds 12g,12h,12i and 12k showed greater degree of antibacterial activity against 
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B.coccus. However, the compounds 12a,12b,12h and 12i showed greater degree of 
antibacterial activity against B.subtilis. The compounds 12a,12f,12h  and 12l showed 
greater degree of antibacterial activity against E.coli. However, the compounds 
12e,12f,12h and 12k showed greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Schiff’s base derivatives tested 
compounds 12a,12c,12f and 12l showed greater degree of antifungal activity against  
A.niger. 
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TABLE NO.12: PHYSICAL CONSTANT OF N-ARYL-1,-4-(p-CHLOROBENZYLOXY)-3-METHOXYPHENYL-1-YL-
AZOMETHINES 
Comp. 
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular 
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent
System
10 Calcd. 8
Found
9 
12a -C6H5 C22H20ClNO2S 397.50 160 0.44 55 3.52 3.50 S2 
12b -4-OCH3-C6H4 C21H17Cl2NO2 386.00 162 0.55 56 3.63 3.60 S2 
12c -4-Cl-C6H4 C21H17BrClNO2 430.50 180 0.66 74 3.25 3.20 S1 
12d -2,4-(Cl)2-C6H3 C21H18ClNO2 351.50 174 0.68 42 3.98 4.10 S1 
12e -4-OH-C6H4 C21H16Cl3NO2 420.50 190 0.48 36 3.33 3.40 S2 
12f -4-Br-C6H4 C22H20ClNO2 365.50 155 0.58 55 3.83 3.80 S1 
12g -4-NO2-C6H4 C21H17ClFNO2 369.50 174 0.63 52 3.79 3.85 S1 
12h -4-NH2-C6H4 C21H17Cl2NO2 386.00 185 0.64 65 3.63 3.58 S1 
12i -2-OH-C6H4 C21H16Cl3NO2 420.50 210 0.50 41 3.33 3.41 S2 
12j -4-CH3-C6H4 C21H16Cl3NO2 420.50 220 0.54 36 3.33 3.35 S1 
12k -2,4-(OCH3)2-C6H3 C23H22ClNO4 411.50 196 0.68 52 3.40 3.45 S1 
12l -4-(O-CH2-C6H5)-C6H4 C21H17ClFNO2 369.50 174 0.71 55 3.79 3.83 S1 
TLC Solvent system : S1 :  Methanol:Dichloromethane(0.4:9.6); S2 : Ethyl acetate : Hexane(40:60) 
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GRAPHICAL CHART NO. 12 : ANTIMICROBIAL ACTIVITY OF  N-ARYL-1,-4-(p-CHLOR-OBENZYLOXY)-3-
METHOXYPHENYL-1-YL-AZOMETHINES 
0
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m
m
B.coccus 14 13 15 11 13 14 19 16 18 14 18 11 20 21 18 20 0
B.subtilis 20 19 12 14 15 11 11 18 22 17 12 14 24 24 17 18 0
E.coli 20 16 18 12 19 22 10 23 17 15 16 22 22 25 24 18 0
P.vulgaris 11 14 12 13 20 18 16 17 12 12 18 13 21 25 25 15 0
A.niger 20 15 20 18 10 20 12 16 17 15 12 19 0 0 0 0 24
12a 12b 12c 12d 12e 12f 12g 12h 12i 12j 12k 12l Ampicillin
Amoxi
cillin
Norflo
xacin
Benzyl 
Penicil
lin
Griseo
fulvin
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PART-II : STUDIES ON AMINES 
 
INTRODUCTION 
  
         Arylamine derivatives have been found to be potent drug in pharmaceutical 
Industries and possess a wide spectrum of biological activity. Arylamines are also  well 
known interemediate for the preparation of synthetic hormones,azetidinone, 
thiazolidinone, formazone, arylacetamide and many other derivatives. These are the 
compounds contain characteristic amine group. 
  
SYNTHETIC ASPECTS 
2. General account of the summary of reaction of Schiff’s base  with sodium 
borohydride 
         
R
1
N R
NaBH4 R
1
NH R
 
2.    A simple and convenient procedure allows the reductive amination of 
aldehydes and ketones using sodium borohydride as reducing agent and boric acid, p-
toluenesulfonic acid monohydrate or benzoic acid as activator under solvent-free 
conditions.1 
           
R R1
O
+ NH
R
2
R
3
NaBH4
H3BO3
R
R1
N
R2
R3
 
3. C. Kison and N. Meyer2  represents a simple and flexible method for the 
synthesis of highly substituted unsymmetrical 1,2-diamines. In addition , either the syn- 
or anti-configurated diamine can be obtained , depending of the choice of the workup and 
reduction conditions. 
 
THERAPEUTIC IMPORTANCE 
          Arylamines exhibit a wide range of pharmacological activities like antifungal, 
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antibacterial, antiviral, antiinflammatory etc. Sertraline hydrochloride (I) is an 
antidepressant of the selective serotonin reuptake inhibitor class. It was  introduced to the 
market by Pfizer in 1991. Sertraline is primarily used to treat major depression in adult 
outpatients as well as obsessive-compulsive, panic and social anxiety disorders in both 
adults and children. In 2007, it was the most prescribed antidepressant on the U.S. retail 
market, with 29,652,000 prescriptions. 
 
                    
N
CH3
Cl
Cl
NaBH4
(I)
NH
CH3
Cl
Cl
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SECTION – I 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(p-CHLOROBENZYLO- 
XY)-3-METHOXY-BENZYLARYLAMINES 
 
          4-(p-Chlorobenzyloxy)-3-methoxy-benzylarylamines of type (XIII) have been 
prepared by the reduction of N-Aryl-1,-4-(p-chlorobenzyloxy)-3-methoxyphenyl-1-yl-
azomethines with Sodium cyanoborohydride in methanol at ambient temperature 
  
NH
O
O
CH3
Cl
R
Type(XIII)Type(XII) R=Aryl
N
O
O
CH3
Cl
R
Sodiumcyanoborohydride
 
              
                The structure elucidation of synthesized compounds has been done on the basis 
of Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and 
further supported by Mass spectrometry. Purity of all compounds have been checked by 
thin layer chromatography. All the compounds have been evaluated for their in vitro 
biological assay like antibacterial activity towards Gram positive and Gram negative 
bacterial strains and antifungal activity towards A.niger at a concentration of 40µg. The 
biological activities of synthesized compounds were compared with standard drugs.  
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REACTION SCHEME
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IR SPECTRAL STUDIES OF 4-(p-CHLOROBENZYLOXY)-3-METHOXY-N-(p-
THIOMETHOXYPHENYL)-BENZYLAMINE 
 
Instrument : Spectrum One 69888 Spectrophotometer; Frequency range : 4000-400 cm-1 
(KBr disc) 
Type 
Vibration  
mode 
Frequency in cm-1 Ref. 
Observed  Reported 
Alkane C-H str. (asym.) 2968.11 2975-2950 A 
-CH3 C-H str. (sym.) 2863.60 2880-2860 “ 
 C-H def. (asym.) 1468.83 1470-1435 “ 
Aromatic C-H str. 3079.35 3090-3030 “ 
 C=C str. 1518.15 1540-1480 “ 
 C-H i.p. (def.) 1103.43 1125-1090 “ 
 C-H o.o.p. (def.) 827.17 835-810 “ 
Methoxy C-O str. 1233.43 1260-1200 “ 
Halide C-Cl str. 755.95 800-600 “ 
Ether Ar-O-C str. 1214.33 1260-1200 “ 
Imine C=N str. 1574.20 1580-1550 “ 
 
  
O
O
CH3
Cl
NH S
CH3
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NMR SPECTRAL STUDIES OF    4-(p-CHLOROBENZYLOXY)-3-METHOXY-
N-(p-THIOMETHOXYPHENYL)-BENZYLAMINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (400 
MHz) 
  No. 
Chemical 
Shift 
δ ppm 
Multiplicity No. of protons 
Coupling 
constant 
Hz 
Assignment 
of proton(s) 
1. 2.4 s 3 -- 8 
2. 3.86 s 3 -- 7” 
3. 3.99 s 1 -- 9 
4. 4.22 s 2 -- 7 
5. 5.09 s 2 -- 1’ 
 
6. 6.56-7.37 m 11 -- 
3’,7’ 
6,2”,6” 
2,5,4’,6’,3”,
5” 
Total No. of protons  22 
 
 
1
2
34
5
6
7
8
1'
2'
3'
4'
5'
6'
7'
1"
2" 3"
4"
5"6"
7"
O
O
CH3
Cl
NH S
CH3
9
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MASS SPECTRAL STUDIES OF 4-(p-CHLOROBENZYLOXY)-3-METHOXY-N-(p-THIOMETHOXYBENZYLAMINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
O CH3
Cl
NH S
CH3
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MASS FRAGMENTATION 
[Base peak]
M/z : 353.11
M/z : 289.11
M/z : 248.06
M/z : 229.11 M/z : 153.07
M/z : 139.04
M/z : 112.0M/z : 142.1
+
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+
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+
o
+
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+
o
+
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(p-CHLOROBENZYLO- 
XY)-3-METHOXY-BENZYLARYLAMINES 
 
(A) Synthesis of N-(Thiomethoxyphenyl)-1,-4-(p-chlorobenzyloxy)-3-methoxyphe-                      
nyl-1-yl-azomethines 
                               See [B],Part-I, Section-I (B). 
(B) Synthesis of 4-(p-Chlorobenzyloxy)-3-methoxy-N-(p-thiomethoxyphenyl)-benzy- 
lamine  
 
           A solution of N-(p-Thiomethoxyphenyl)-1,-4-(p-chlorobenzyloxy)-3-
methoxyphenyl-1-yl-azomethine(3.97g,0.01M) and Sodiumcyanoborohydride 
(1.25g,0.02M) in ethanol(40ml) was stirred  for 10 hr. The separated solid was filtered out 
and crystallized from ethanol. Yield 55 %, m.p 1350 C. (C22 H22ClNO2; Required: C,66.07; 
H, 5.54; N, 3.35; Found: C, 66.20 ; H, 5.62; N,3.38 %. Similarly, other 4-(p-
Chlorobenzyloxy)-3-methoxy-benzylarylamines were prepared. The physical data are 
recorded in Table No. 13. 
              (C) Biological evaluation of 4-(p-Chlorobenzyloxy)-3-methoxy-benzylarylamines 
 
                                 Antimicrobial testing were carried out as described in [A], Part-I, Section-I(C). 
               The zones of inhibition of test solutions are reported in Graphical Chart No. 13. 
 
CONCLUSION 
 
Antibacterial activity 
           The screening data indicated that among Amine derivatives tested compounds 
13a,13d,13h and 13i showed greater degree of antibacterial activity against B.coccus. 
However, the compounds 13a,13d,13g and 13i showed greater degree of antibacterial 
activity against B.subtilis. The compounds 13c,13d,13g  and 13k showed greater degree 
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of antibacterial activity against E.coli. However, the compounds 13a,13c,13d and 13e 
showed greater degree of antibacterial activity against P.vulgaris. 
 
Antifungal activity 
           The screening data indicated that among Amine derivatives tested compounds 
13a,13c,13d and 13f showed greater degree of antifungal activity against  A.niger. 
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TABLE NO. 13 :   PHYSICAL CONSTANTS OF 4-(p-CHLOROBENZYLOXY)-3-METHOXY-BENZYLARYLAMINES 
             TLC Solvent system: S1 : Methanol: Dichloromethane(0.4:9.6), S2 : Ethyl acetate : Hexane(40:60) 
Comp. 
No. 
1 
R 
2 
Molecular 
Formula 
3 
Molecular 
Weight 
4 
M.P. 
0C 
5 
Rf* 
Value 
6 
Yield 
% 
7 
% of Nitrogen Solvent
system 
10 Calcd.8
Found
9 
13a -C6H5 C22H22ClNO2S 399.50 140 0.42 55 3.50 3.55 S2 
13b -4-OCH3-C6H4 C21H19Cl2NO2 388.00 156 0.43 42 3.61 3.65 S2 
13c -4-Cl-C6H4 C21H19BrClNO2 432.50 165 0.52 63 3.24 3.30 S1 
13d -2,4-(Cl)2-C6H3 C21H20ClNO2 353.50 163 0.56 52 3.96 4.10 S1 
13e -4-OH-C6H4 C21H18Cl3NO2 422.50 169 0.52 55 3.31 3.40 S1 
13f -4-Br-C6H4 C22H22ClNO2 367.50 186 0.41 47 3.81 3.90 S2 
13g -4-NO2-C6H4 C21H19ClFNO2 371.50 175 0.45 49 3.77 3.85 S2 
13h -4-NH2-C6H4 C21H19Cl2NO2 388.00 160 0.63 66 3.61 3.75 S1 
13i -2-OH-C6H4 C21H18Cl3NO2 422.50 173 0.62 62 3.31 3.40 S1 
13j -4-CH3-C6H4 C21H18Cl3NO2 422.50 182 0.65 55 3.31 3.42 S1 
13k -2,4-(OCH3)2-C6H3 C23H24ClNO4 413.50 183 0.55 45 3.38 3.35 S1 
13l -4-(O-CH2-C6H5)-C6H4 C21H19ClFNO2 371.50 175 0.52 42 3.77 3.65 S1 
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GRAPHICAL CHART NO. 13: ANTIMICROBIAL ACTIVITY OF 4-(p-CHLOROBENZYLO- XY)-3-METHOXY-
BENZYLARYLAMINES 
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B.coccus 18 12 15 18 14 16 12 20 20 15 12 14 20 21 18 20 0
B.subtilis 18 14 12 18 13 17 20 14 18 18 15 12 24 24 17 18 0
E.coli 15 18 20 21 14 19 22 14 15 17 21 18 22 25 24 18 0
P.vulgaris 18 14 19 22 20 17 12 14 11 16 14 11 21 25 25 15 0
A.niger 20 15 18 22 10 20 17 15 16 13 17 14 0 0 0 0 24
13a 13b 13c 13d 13e 13f 13g 13h 13i 13j 13k 13l Ampicillin
Amoxi
cillin
Norflo
xacin
Benzyl 
Penicil
lin
Griseo
fulvin
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